The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis

Mohammad Zamani¹, Mahtab Zarei², Mahlagha Nikbaf-Shandiz³, Shabnam Hosseini⁴, Farideh Shiraseb⁵* and Omid Asbaghi⁶,⁷*

¹Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran, ²Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran, ³Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, ⁴Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁵Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran, ⁶Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁷Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Cardiovascular disease (CVD) is a major concern today. Herbal medicine is one helping way to control CVD risks. One conclusive of herbal medicine is Berberine (BBR) and converse about it still exists, to clarify this issue, this meta-analysis was performed. PubMed/Medline, Scopus, and Web of Science were searched for RCTs in adults on the effect of BBR supplementation on CVD risk factors up to July 2022. The pooled results showed BBR significantly reduced triglyceride (WMD = −23.70 mg/dl; 95%CI = −30.16, −17.25; P < 0.001), total cholesterol (WMD = −20.64 mg/dl; 95%CI = −23.65, −17.63; P < 0.001), low-density lipoprotein WMD = −9.63 mg/dl; 95%CI, −13.87, −5.39; P < 0.001), fasting blood glucose (FBG) (WMD = −7.74 mg/dl; 95%CI = −10.79, −4.70; P < 0.001), insulin (WMD = −3.27 mg/dl; 95%CI = −4.46, −2.07; P < 0.001), HbA1c (WMD = −0.45%; 95%CI = −0.68, −0.23; P < 0.001). HOMA-IR (WMD = −1.04; 95%CI = −1.55, −0.52; P < 0.001), systolic blood pressure (WMD = −5.46 mmHg; 95%CI = −8.17, −2.76; P < 0.001), weight (WMD = −0.84; 95%CI = −1.34, −0.34; P < 0.001), body mass index (WMD = −0.25 kg/m²; 95%CI = −0.46, −0.04; P = 0.020), while increased high-density lipoprotein (HDL) (WMD = 1.37 mg/dl; 95%CI 0.41,2.23; P = 0.005). The optimal dose of BBR was 1 g/day for TG, TC, and weight, 1.8 g/day for insulin and HOMA-IR, and 5 g/day for HDL. FBG’s most efficient time frame was 40 weeks from the beginning of supplementation, whereas DBP and waist circumference was 50 weeks. In conclusion, the lipid profile, FBG balance, obesity parameters, and SBP were improved with BBR supplementation.

Systematic review registration: CRD42022347004.

KEYWORDS
berberine, cardiovascular risk factors, systematic review, meta-analysis, adult
Introduction

Cardiovascular disease (CVD), a general term for heart and blood vessel disorders, is still the first-ranked cause of death despite recent advances in its management (1). World Health Organization (WHO) has noted that ~19.7 million people die every year due to CVDs, which equals 32 % of all deaths globally (1). Common cardiovascular risk factors, such as dyslipidemia and hyperglycemia, are mainly influenced by modifiable lifestyle and dietary factors (2, 3). To date, the cardio-protective effects of many dietary patterns, food groups, and functional foods have been investigated (4).

Traditional herbs have gained more attention since they are often cheaper, more locally available, with fewer side effects than synthetic drugs. Berberine (BBR), a plant alkaloid with known pharmacological properties extracted from Chinese traditional herbs (5), has been the subject of more research about its ameliorative effect on CVD risk factors (6); through suggested mechanisms (7). The major risk factors for CVD are well-established and they include metabolic syndrome components (dyslipidemia, hypertension, diabetes or insulin resistance, and abdominal obesity), inflammatory markers, and liver enzymes (8). These risk factors contribute to future CVD, stroke, diabetes, and mortality in individuals (8). BBR supplementation could be effective in either primary prevention or secondary prevention of CVD (6, 9, 10). Preclinical (animal, in vitro) studies demonstrate that BBR has positive effects on lowering blood lipids, blood glucose, and controlling weight and blood pressure (10, 11). Previous meta-analyses have conducted on the effect of BBR administration on CVD risk factors, but they are not comprehensive and conclusive. BBR supplementation ameliorated MetS components (dyslipidemia, insulin resistance, hypertension, obesity) in previous meta-analyses (12–16). In addition, the effect of BBR supplementation on other CVD risk factors such as inflammatory markers and liver enzymes has been assessed by other meta-analyses (13, 17, 18). These meta-analyses have either assessed a single MetS component (12, 17), showed null/inconclusive results at the end (13, 14, 19), or included a few studies in their meta-analysis (12, 14).

Therefore, because the existing literature still lacks an appropriate comprehensive answer to whether BBR is effective on CVD risk factors or not, with finding the optimal dose and duration, we aimed to perform a novel comprehensive dose-response meta-analysis on the effect of BBR on all CVD risk factors in adults.

Materials and methods

Search strategy and study selection

The current study was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (20). The protocol has been registered at PROSPERO (CRD42022347004).

We conducted a systematic literature search in the following databases without any time, length of study, or language restrictions: PubMed/Medline, Scopus, Web of Science, EMBASE, the Cochrane databases, and Google Scholar (all of them up to July 2022). The framework that we used for our search was the PICO (Participant, Intervention, Comparison/Control, Outcome) strategy, which is recommended by Cochrane: (1) participants; (2) intervention group (which was treated by BBR); (3) comparison/Control group (non-BBR supplementation), and (4) outcome (all of the CVD risk factors that will be mentioned in inclusion criteria section). The full search strategy and the terms used to search in each database could be found in detail in Figure 1. We additionally screened the reference lists of previous systematic reviews and meta-analyses in order not to miss any related studies. To make sure that no studies were overlooked, we started the data collection process by using a combination of MeSH terms and keywords. The following keywords were manually used to search all related study reference lists: berberine OR huangliansu OR berberinum OR Xiaopojian OR barberry OR “Berberis vulgaris” OR Berberis) AND (Intervention OR “Intervention Study” OR Comparison/Control, Outcome) strategy, which is recommended by Cochrane: (1) participants; (2) intervention group (which was treated by BBR); (3) comparison/Control group (non-BBR supplementation), and (4) outcome (all of the CVD risk factors that will be mentioned in inclusion criteria section). The full search strategy and the terms used to search in each database could be found in detail in Figure 1. We additionally screened the reference lists of previous systematic reviews and meta-analyses in order not to miss any related studies. To make sure that no studies were overlooked, we started the data collection process by using a combination of MeSH terms and keywords. The following keywords were manually used to search all related study reference lists: berberine OR huangliansu OR berberinum OR Xiaopojian OR barberry OR “Berberis vulgaris” OR Berberis) AND (Intervention OR “Intervention Study” OR “Intervention Studies” OR Randomized OR Random OR Randomly OR Placebo OR “Clinical Trial” OR Trial OR Trials OR “Randomized Clinical Trial” OR RCT OR blinded OR “double blind” OR “double blinded” “Controlled Trial” “Randomized Controlled Trial” OR “Controlled Clinical Trial” OR “Pragmatic Clinical Trial” OR “Cross-Over Studies” OR

Abbreviations: CVD, Cardiovascular disease; WHO, World Health Organization; BBR, Berberine; CRP, C reactive protein; BMI, body mass index; PICO, Participant, Intervention, Comparison/Control, Outcome; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment-insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactive protein; IL-6, interleukin-6; WC, waist circumference; ALT, Alanine transaminase; GRADE (Grading of Recommendations Assessment, Development, and Evaluation), WMD, weighted mean difference, AMPK, AMP-activated protein kinase; P38K, phosphoinositide 3-kinase; NF-kB, nuclear factor kappa B; TNF-α, tumor necrosis factor alpha; PPARγ, peroxisome proliferator-activated receptor γ; CREB, cAMP-response element-binding protein; WHR, waist to hip ratio; HepG2, human hepatoma cell line; MAPK, mitogen-activated protein kinase; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, LDL receptor; HMG-CoA, β-hydroxy-β-methylglutaryl-CoA; ACC, acetyl-coenzyme A carboxylase; GLUT4, glucose transporter type 4; IL1β, Interleukin 1beta; NF-kB, nuclear factor kappa B; CREB, cAMP-response element-binding protein.
“Cross-Over” OR “Cross-Over Study” OR Parallel OR “Parallel Study” OR “Parallel trial”).

**Study selection**

To include clinical studies, we considered the following criteria: (1) Only randomized clinical trials (parallel or crossover). (2) The intervention duration $\geq 1$ week; (3) Studies with adult human subjects ($\geq 18$ years); (5) Studies that reported mean $\pm$ standard deviation (SD) or other effect sizes from which the calculation of mean and SD was possible; (6) Studies that examined the effect of BBR supplementation on triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL), fasting blood glucose, hemoglobin A1c (HbA1c), serum insulin, homeostasis model assessment-insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), C-reactive protein (CRP), interleukin-6, (IL-6), weight, waist circumference (WC), body mass index (BMI), aspartate transaminase (AST) and alanine transaminase (ALT). The exclusion criteria were as follows: (1) studies on animal subjects and in-vitro studies; (2) studies on children and adolescents; (3) grey literature, reviews, conference abstracts, editorials, and books; (4) RCTs that did not have control/placebo groups.

**Data collection**

MZ and OA independently screened the titles and abstracts of studies and discussed them with each other in case of any disagreement. Then, after re-assessment, MZ and OA extracted the following information from the included studies: first author’s name, year of publication, country, type of clinical trial, participant characteristics (mean age, BMI, sex), duration of intervention, randomization, blinding, adverse effects sample size, the number of participants in the intervention and control groups, form and dosage of supplemented BBR, the health
status of participants (healthy, diabetes, etc.), and outcome values. To solve any inconsistency in dosage, all of the BBR supplementation doses were converted to g/day.

**Assessment of studies quality**

Included studies were screened for any source of bias, including random sequence generation, allocation concealment, participant and staff blindness, outcome assessor blinding, incomplete outcome data, selective reporting, and other biases using the Cochrane Collaboration tool (21) (Table 2). Then, three groups of high (general high risk > 2 high risk), moderate (general moderate risk = 2 high risk), and low (general low risk < 2 high risk) risk of bias were defined. Two reviewers (MZ and OA) independently assessed the quality of the work, and any conflicting opinions were settled by discussion.

**Assessment of certainty**

The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach was used to assess and summarize the certainty of evidence among the included studies, as described previously (Table 4) (22).

**Statistical analysis**

Statistical analyses were conducted using Stata version 11.0 (Stata Corp, College Station, TX). All tests were two-tailed with P-values < 0.05 considered statistically significant. The pooled weighted mean difference (WMD) was calculated using a random-effects model (23). Mean differences in our outcomes were calculated from baseline to the after-intervention period between BBR supplementation and control groups. The SD of the mean difference was calculated using the following formula: SD = square root [(SD at baseline)² + (SD at the end of study)² – (2 r × SD at baseline × SD at the end of study)] / (24). In each study reporting standard errors (SEs), 95 percent confidence intervals (CIs), or interquartile ranges (IQRs), to transform these values into SDs, we used Hozo et al. approach. We used the [SD = SE × √(n / (n = the number of individuals in each group))] formula to calculate SD (25). A correlation coefficient of 0.8 was used for r (26). After visual inspection of forest plots or Cochrane’s Q test (27), heterogeneity was evaluated using the I² statistic (I² = 0.05 and I² > 40%) (28). Subgroup analysis was performed to explore the source of heterogeneity. Subgroups were selected based on the required minimum number of studies according to the criteria set by Fu et al., where there should be at least 6–10 studies for continuous and a minimum of 4 studies for categorical subgroup variables (29, 30). Subgroup analyses were performed regarding BBR dosage (<1 g/d and >1 g/d), intervention duration (<8 weeks and >8 weeks) sex (male, female), health status [dyslipidemia, type 2 diabetes, Metabolic Syndrome, non-alcoholic fatty liver disease (NAFLD)], baseline of TG (<100, ≥100 mg/dl), TC (<200, ≥200 mg/dl), LDL (<100, ≥100 mg/dl), HDL (<40, ≥40 mg/dl), FBG (<100, >100 mg/dl), SBP (<120, ≥120 mmHg), DBP (<80, ≥80 mmHg), and baseline BMI [normal (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²) and obese (≥30 kg/m²)], and category of risk of bias in studies (high, moderate, low). Studies examining the impact of BBR supplementation on CVD risk variables used the Begg’s and Eager tests according to the number of studies for every outcome and the funnel plot test to evaluate publication bias (31, 32). Using the leave-one-out technique (removing one trial at a time and recalculating the impact size), we have done sensitivity analysis to establish how many inferences were dependent on a single sample to examine each study’s impact on the pooled effect size (33). The possible impact of BBR (g/d) dose and duration on CVD risk variables was evaluated using meta-regression. In order to evaluate the effect of BBR supplementation on CVD risk variables, we also employed a non-linear model to include the associated dose-response data from several trials (34, 35).

**Results**

**Study selection**

The selection process of the included studies is presented in Figure 1. A database search resulted in identifying a total of 4,684 studies, including PubMed (n = 2,153), ISI Web of Science (n = 867), and Scopus (n = 1,664). A total of 1,266 duplicated studies were excluded, and 3,418 studies were screened based on title and abstract. After screening, 3,348 irrelevant studies were excluded, and 70 full-text studies were considered. In the end, 21 studies were excluded due to reporting non-desired outcomes. As a result, 49 studies were included in the systematic and meta-analysis review (36–84).

**Study characteristics**

The characteristics of included studies are presented in Table 1. The WMD and 95% CI of TG (mg/dl), TC (mg/dl), LDL (mg/dl), HDL (mg/dl), FBG (mg/dl), insulin (mg/dl), HbA1c (%), HOME-IR, SBP (mmHg), DBP (mmHg), CRP (mg/l), IL-6 (ng/l), weight (kg), BMI (kg/m²), WC (cm), ALT (U/L), AST (U/L), and their changes are presented in Figures 2A–Q respectively. The studies were published between 2004 and 2022 and were carried out in China (n = 22) (36, 39–43, 46, 47, 52, 53, 56, 59, 71–80), Iran (n = 19) (37, 38, 44, 45, 50, 51, 54, 57, 61, 63–65, 67, 69, 70, 81–83, 85), Italy (n = 2) (48, 84), Mexico (n = 2) (55, 62), India (n = 2) (60, 66), USA (n = 1) (49), and Pakistan.
| Studies       | Country | Study design            | Participant                  | Sample size and sex | Sample size (week) | Trial duration (week) | Means age | Means BMI | Intervention | Adverse effects |
|--------------|---------|-------------------------|------------------------------|---------------------|-------------------|-----------------------|-----------|-----------|--------------|-----------------|
| Kong et al.  | China   | R, DB, PC, parallel     | Dyslipidemia                 | M/F: 43             | 32                | 11                    | 12        | NR        | NR           | 1 Placebo        |
| Wu et al.    | China   | R, PC, parallel         | Renal transplanted recipients| M/F: 104            | 52                | 52                    | 12        | NR        | NR           | 1 Control group  |
| Zhang et al. | China   | R, DB, PC, parallel     | Type 2 diabetes              | M/F: 110            | 58                | 52                    | 12        | 51 ± 9    | 51 ± 10       | 1 Placebo        |
| Yin et al.   | China   | R, PC, parallel         | Type 2 diabetes              | M/F: 31             | 15                | 16                    | 12        | 25–75     | 25–75         | 1 Control group  |
| Kong et al.  | China   | R, PC, parallel         | Dyslipidemia                 | M/F: 39             | 23                | 16                    | 8         | NR        | NR           | 1 Control group  |
| Zhao et al.  | China   | R, PC, parallel         | Dyslipidemia                 | M/F: 51             | 35                | 16                    | 12        | 43.6 ± 7.8 | 43.9 ± 8.9   | 1 Silymarin      |
| Ebrahimi-Mamaghani et al. | Iran | R, PC, parallel         | Metabolic Syndrome           | M/F: 38             | 19                | 19                    | 8         | 59.1 ± 12.2 | 53.8 ± 9      | 1 Placebo        |
| Golzarand et al. | Iran | R, PC, parallel         | Type 2 diabetes              | M/F: 38             | 19                | 19                    | 4         | 59.1 ± 12.2 | 53.8 ± 9      | 1 Placebo        |
| Gu et al.    | China   | R, DB, PC, parallel     | Type 2 diabetes              | M/F: 60             | 30                | 30                    | 12        | 51 ± 9    | 50 ± 10       | 1 Placebo        |
| Zhang et al. | China   | R, PC, parallel         | Type 2 diabetes              | M/F: 76             | 50                | 26                    | 8         | 57 ± 8    | 56 ± 11       | 1 Metformin      |
| Wei et al.   | China   | R, PC, parallel         | Polycystic Ovary syndrome    | F: 59               | 31                | 28                    | 12        | 25.74 ± 2.66 | 26.75 ± 2.62  | 1.5 Placebo      |
| Meng et al.  | China   | R, PC, parallel         | Acute coronary syndrome      | M/F: 130            | 61                | 69                    | 4         | 63.07 ± 10.41 | 63.28 ± 10.03 | 0.9 Control group |
| Shidfar et al.| Iran    | R, DB, PC, parallel     | Type 2 diabetes              | M/F: 42             | 21                | 21                    | 12        | 53.1 ± 6.3 | 52.2 ± 4.9   | 3 Control group  |
| Yan et al.   | China   | R, DB, PC, parallel     | Nonalcoholic fatty liver disease | M/F: 124           | 62                | 62                    | 16        | 50.69 ± 9.75 | 50.49 ± 10.72 | 1.5 Control group |
| Derosa et al.| Italy   | R, DB, PC, parallel     | Healthy subjects             | M/F: 144            | 144               | 144                   | 12        | 53 ± 11   | 53 ± 11       | 1 Placebo        |

(Continued)
TABLE 1 (Continued)

| Studies          | Country    | Study design | Participant                          | Sample size and sex | Sample size | Trial duration (week) | Means age | Means BMI | Intervention | Adverse effects |
|------------------|------------|--------------|--------------------------------------|---------------------|-------------|-----------------------|-----------|-----------|--------------|-----------------|
| Cheng et al. (42) | China      | R, PC, parallel | Healthy subjects                     | M/F: 23             | 12          | 11                    | 4         | 53.75 ± 5.97 | 52.7 ± 4.55 | 22.56 ± 3.1 | 22.67 ± 1.91 | 1.2 Control group |
| Pérez-Rubio et al. (62) | Mexico      | R, DB, PC, parallel | Metabolic Syndrome                  | M/F: 24             | 12          | 12                    | 12        | 38.1 ± 2.7   | 36.9 ± 3   | 36.1 ± 2.3 | 34.2 ± 3.6 | 1.5 Placebo |
| Kashkooli et al. (50) | Iran         | R, PC, parallel | Nonalcoholic fatty liver disease     | M/F: 80             | 40          | 40                    | 12        | 43.2 ± 8.45  | 42.97 ± 8.56| NR           | NR            | 0.75 Placebo |
| An et al. (36)  | China       | R, DB, PC, parallel | Polycystic ovary syndrome           | F: 87               | 44          | 43                    | 12        | 28.2 ± 3.8   | 28.4 ± 4   | 24.6 ± 3.1 | 24.2 ± 3.2 | 1.5 Placebo |
| Zilaee et al. (81) | Iran        | R, DB, PC, parallel | Metabolic syndrome                  | M/F: 106            | 53          | 53                    | 6         | 38.96 ± 9.04 | 40.89 ± 9.61| 31.54 ± 3.92 | 32.37 ± 5.01 | 0.6 Placebo |
| Fei-qii et al. (46) | China        | R, PC, parallel | Acute ischemic stroke               | M/F: 44             | 16          | 28                    | 12        | 63.31 ± 8.1  | 66.25 ± 8.83| NR           | NR            | 1.2 Control group |
| Dai et al. (43) | China       | R, PC, parallel | Type 2 diabetes                     | M/F: 69             | 36          | 33                    | 104       | 55.31 ± 11.79 | 53.06 ± 10.36| 24.5 ± 4.01 | 24.1 ± 4.36 | 0.3 Control group |
| Yan et al. (75) | China       | R, PC, parallel | Nonalcoholic fatty liver disease     | M/F: 124            | 62          | 62                    | 16        | 50.72 ± 9.76 | 50.64 ± 10.69| 28.06 ± 4.17 | 27.27 ± 2.8 | 1.5 Control group |
| Zilaee et al. (82) | Iran        | R, DB, PC, parallel | Metabolic syndrome                  | M/F: 106            | 53          | 53                    | 6         | 38.96 ± 9.04 | 40.89 ± 9.61| 31.54 ± 3.92 | 32.37 ± 5.01 | 0.6 Placebo |
| Kashkooli et al. (50) | Iran        | R, PC, parallel | Nonalcoholic fatty liver disease     | M/F: 80             | 40          | 40                    | 12        | 43.65        | 42.97       | NR           | NR            | 0.75 Placebo |
| Lazavi et al. (85) | Iran        | R, PC, parallel | Type 2 diabetes                     | M/F: 42             | 21          | 21                    | 8         | 57 ± 8       | 54 ± 7      | 29 ± 4       | 28 ± 3       | 200 ml Control group |
| Chang et al. (41) | China       | R, PC, parallel | Nonalcoholic fatty liver disease     | M/F: 80             | 41          | 39                    | 16        | 51.2 ± 9.4   | 50.8 ± 10.4 | 27.4 ± 4.1   | 27.3 ± 3      | 1.5 Control group |
| Guarino et al. (48) | Italy       | R, DB, PC, parallel | Type 2 diabetes                     | M/F: 136            | 68          | 68                    | 52        | 56 ± 8       | 55 ± 9      | 34 ± 4       | 34 ± 5        | 1 Placebo |

Additional information:
- One patient reported headache and two patients reported transient flatulence.
- No significant adverse effect was reported.
- The commonly reported study side effects were nausea.
- Adverse events were mild and mainly occurred in digestive system.

(Continued)
| Studies                | Country | Study design | Participant | Sample size and sex | Sample size (week) | Trial duration (week) | Means age IG | Means BMI IG | Intervention | Adverse effects |
|------------------------|---------|--------------|-------------|---------------------|------------------|-----------------------|--------------|--------------|--------------|----------------|
| Mansouri et al. (57)   | Iran    | R, PC, parallel | Type 2 diabetes | M/F: 60            | 30 30 12         | 30 30 38              | 48.2 ± 4.3   | 48.2 ± 4.3   | NR NR       | 200 ml Placebo NA |
| Sharma et al. (66)     | India   | R, PC, parallel | Type 2 diabetes | M/F: 60            | 30 30 38         | 30–60 30–60          | NR NR       | NR NR       | 1.5 Conventional | No adverse effect was observed |
| Sharma et al. (66)     | India   | R, PC, parallel | Type 2 diabetes | M/F: 60            | 30 30 38         | 30–60 30–60          | NR NR       | NR NR       | 3 Conventional | NA |
| Asemani et al. (38)    | Iran    | R, TR, PC, parallel | Women with Benign Breast Disease | F: 85 | 44 41 8 | 36.17 ± 7.6 38.45 ± 6.9 | NR NR | NR NR | 480 ml Placebo | No adverse effect was reported. |
| Rashidi et al. (63)    | Iran    | R, DB, PC, parallel | Type 2 diabetes | M/F: 84            | 42 42 4          | 50.18 ± 4.22 45.12 ± 9.55 | 29.81 ± 4.1 29.07 ± 5.07 | 1 Placebo | NA |
| Lazari et al. (54)     | Iran    | R, PC, parallel | Type 2 diabetes | M/F: 46            | 23 23 8          | 56.86 ± 8.47 53.95 ± 6.57 | 29.22 ± 3.98 27.78 ± 3.45 | 200 ml Control group | No serious adverse effect were reported. |
| Tahmasebi et al. (70)  | Iran    | R, DB, PC, parallel | Type 2 diabetes | M/F: 80            | 40 40 6          | 54.05 ± 8 53.07 ± 7.74 | NR NR | NR | 1.5 Placebo | NA |
| Cao et al. (39)        | China   | R, PC, parallel | Metabolic syndrome | M/F: 80 | 40 40 4 | 65.5 ± 1.8 65.6 ± 1.8 | NR NR | NR | 1.2 Control group | Nausea and vomiting |
| Aryaeian et al. (37)   | Iran    | R, DB, PC, parallel | Rheumatoid Arthritis patients | M/F: 62 | 31 31 12 | 48.61 ± 11.69 47.1 ± 10.75 | 27.9 ± 6.06 29.46 ± 5.7 | 3 Placebo | NA |
| Sanjari et al. (65)    | Iran    | R, TR, PC, parallel | Type 2 diabetes | M/F: 80            | 42 38 12         | 51.8 ± 9.3 43.5 ± 10 | 27.2 ± 4.9 27.7 ± 5.3 | 0.48 Control group | No significant adverse effect was reported |
| Soltani et al. (69)    | Iran    | R, PC, parallel | Type 2 diabetes | M/F: 65            | 30 35 8          | 56.1 ± 7.2 57.6 ± 7.7 | 29.7 ± 4.4 29.5 ± 4.4 | 1 Control group | NA |
| Khorshidi-Sedehi et al. (51) | Iran | R, DB, PC, parallel | Rheumatoid arthritis patients | M/F: 62 | 31 31 12 | 48.61 ± 11.69 47.1 ± 10.75 | 27.9 ± 6.06 29.46 ± 5.7 | 1.5 Control group | NA |
| Li et al. (56)         | China   | R, DB, PC, parallel | Schizophrenia | M/F: 49            | 27 22 8          | 44.74 ± 10.59 41.14 ± 11.51 | 24.73 ± 4.4 23.78 ± 2.6 | 0.9 Placebo | Abdominal distention, constipation, diarrhea, sinus bradycardia |

(Continued)
| Studies | Country | Study design | Participant | Sample size and sex | Sample size | Trial duration (week) | Means age | Means BMI | Intervention | Adverse effects |
|---------|---------|--------------|-------------|---------------------|-------------|-----------------------|-----------|-----------|-------------|-----------------|
| Emamat et al. (45) Iran | R, SB, PC, parallel | Hypertension | M/F: 84 | 42 42 | 8 | 53.62 ± 10.34 54.5 ± 10.13 | 28.21 ± 2.03 27.83 ± 2.32 | 10 | Placebo | NA |
| León-Martínez et al. (55) Mexico | R, DB, PC, parallel | Dyslipidemia | M/F: 24 | 12 12 | 12 | 46.8 ± 10.5 44.8 ± 9 | 29 ± 3.3 31.5 ± 4.3 | 1.5 | Control group | NA |
| Memon et al. (58) Pakistan | R, PC, parallel | Type 2 diabetes | M/F: 100 | 50 50 | 12 | 33.4 ± 2.96 33.26 ± 2.6 | 33.5 ± 2.53 34.7 ± 4.7 | 1.5 | Metformin | NA |
| Zhao et al. (86) China | R, DB, PC, parallel | Dyslipidemia | M: 84 | 42 42 | 12 | 49.5 ± 11.1 44.8 ± 13.5 | 26.3 ± 3.7 26.1 ± 3.8 | 1 | Placebo | No significant adverse effect was reported |
| Harrison et al. (49) USA | R, DB, PC, parallel | Type 2 diabetes | M/F: 66 | 33 17 | 18 | 58 ± 10.2 58 ± 10.7 | 36.7 ± 6.88 35 ± 6.18 | 1 | Placebo | Diarrhea and abdominal discomfort |
| Harrison et al. (49) USA | R, DB, PC, parallel | Type 2 diabetes | M/F: 67 | 34 16 | 18 | 53 ± 12.2 58 ± 10.7 | 36.3 ± 6.28 35 ± 6.18 | 2 | Placebo | Diarrhea and abdominal discomfort |
| Chan et al. (40) China | R, DB, PC, parallel | Schizophrenia | M/F: 113 | 58 55 | 12 | 39.3 ± 11.3 36.2 ± 10.8 | 29.3 ± 4.5 29.2 ± 4.2 | 0.6 | Placebo | No serious adverse effect was reported |
| Wang et al. (71) China | R, DB, PC, parallel | Type 2 diabetes | M/F: 175 | 84 91 | 12 | 52.07 ± 10.81 52.56 ± 9.44 | 25.78 ± 3.36 26.26 ± 3.42 | 1.2 | Placebo | NA |
| Nejati et al. (61) Iran | R, PC, parallel | Nonalcoholic fatty liver disease | M/F: 50 | 25 6 | | 40.6 ± 8.8 42.2 ± 3.8 | 30.1 ± 4.1 29.9 ± 3.8 | 6.25 | Control group | NA |
| Mishra et al. (60) India | R, PC, parallel | Polycystic Ovary syndrome | F: 86 | 43 43 | 12 | 27.1 ± 5.1 27.67 ± 5.06 | 24.69 ± 2.99 25.46 ± 2.23 | 1 | Metformin | NA |

IG, intervention group; CG, control group; DB, double-blinded; SB, single-blinded; PC, placebo-controlled; CO, controlled; RA, randomized; NR, not reported; F, female; M, male; NR, not reported.
Adverse effects

The adverse effect was reported in studies including Asemanni et al. (38), Sharma et al. (66), Chan et al. (40), Meng et al. (59), Li et al. (56), Zhang et al. (78), Pérez-Rubio et al. (62), Zhao et al. (79), Sanjari et al. (65), Yin et al. (76), Kong et al. (53), Yan et al. (75), Lazavi et al. (34), Zhang et al. (77), An et al. (36), Cao et al. (39), Derosa et al. (84) and Harrison et al. (49). While no significant adverse effects were reported in some studies (38, 40, 53, 54, 59, 62, 65, 66, 77, 79), other studies reported mild to moderate gastrointestinal adverse effects including nausea, constipation, and diarrhea (36, 39, 49, 56, 73, 75, 76, 84).

Qualitative data assessment

Based on the Cochrane Risk of Bias Assessment tool, a total of 38 studies were considered with a high risk of bias (36, 39, 41–50, 52–54, 57–66, 69, 71–77, 80, 82, 83), six studies had a moderate risk of bias (55, 67, 70, 78, 79, 84) and five studies had a low risk of bias (36–38, 51, 56) (Table 2).

Effects of BBR supplementation on TG

A total of 38 effect sizes from 38 studies were included in the analysis of the effect of BBR supplementation on TG (Figure 2A) (36, 37, 39–42, 44, 47–50, 52–56, 58–63, 65–67, 71, 72, 74–81, 84). BBR significantly reduced TG compared to placebo (WMD = −23.70 mg/dl; 95% CI, −30.16 to −17.25; P < 0.001). The subgroup analysis showed that the effect of BBR on TG was significant in studies conducted on the baseline TG < 150 mg/dl (WMD = −18.18 mg/dl; 95% CI, −23.63 to −12.73; P < 0.001) and ≥150 mg/dl (WMD = −26.34 mg/dl; 95% CI, −33.78 to −18.90; P < 0.001), trial duration ≤8 weeks (WMD = −20.94; 95% CI, −30.70 to −11.17; P < 0.001) and trial duration >8 weeks (WMD = −25.59; 95% CI, −33.31 to −17.86; P < 0.001), intervention dose ≤1 g/d (WMD = −24.96 mg/dl; 95% CI, −38.79 to −11.13; P < 0.001) and >1 g/d (WMD = −24.89 mg/dl; 95% CI, −32.93 to −16.86; P < 0.001), overweight (25–29.9 kg/m²) (WMD = −26.88; 95% CI, −36.98 to −16.78; P < 0.001) and obese (>30 kg/m²) (WMD = −28.93; 95% CI, −44.38 to −13.48; P < 0.001), type 2 diabetes (WMD = −26.40; 95% CI, −33.91 to −18.89; P < 0.001), metabolic syndrome (WMD = −32.17; 95% CI, −59.74 to −4.60; P = 0.022), non-alcoholic fatty liver diseases (WMD = −32.30; 95% CI, −54.36 to −10.24; P = 0.004), and category of trials risk of bias, high risk of bias (WMD = −24.40; 95% CI, −33.40 to −15.66; P < 0.001), moderate risk of bias (WMD = −27.55; 95% CI, −38.65 to −16.46; P < 0.001) (Table 3).

Effects of BBR supplementation on TC

A total of 34 effect sizes from 28 studies were included in the meta-analysis of the effect of BBR supplementation on TC (Figure 2B) (36, 37, 39–42, 44, 47–48, 50, 52–56, 58–61, 63, 65–67, 71, 72, 74–76, 78–81, 84). BBR significantly reduced TC compared to placebo (WMD = −20.64 mg/dl; 95% CI, −23.65 to −17.63; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on TC was significant in studies conducted on the baseline TC < 200 mg/dl (WMD = −12.10 mg/dl; 95% CI, −18.86 to −5.34; P < 0.001), ≥200 mg/dl (WMD = −23.81 mg/dl; 95% CI, −27.55 to 20.06; P = 0.035), trial duration ≤8 weeks (WMD = −18.09; 95% CI, −26.21 to −9.97; P < 0.001) and >8 weeks (WMD = −21.30; 95% CI, −24.74 to 17.86; P < 0.001), intervention dose ≤1 g/d (WMD = −21.30 g/d; 95% CI, −28.23 to −14.36; P < 0.001).
FIGURE 2 (Continued)
FIGURE 2
(Continued)
FIGURE 2
Forest plot detailing weighted mean difference (WMD) and 95% confidence intervals (CIs) for the effect of berberine consumption on (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG (mg/dl); (F) Insulin (mg/dl); (G) HbA1c (%); (H) HOMA-IR; (I) SBP (mmHg); (J) DBP (mmHg); (K) CRP (mg/L); (L) IL-6 (ng/L); (M) weight (kg); (N) BMI (kg/m²); (O) WC (cm); (P) ALT (U/L); and (Q) AST (U/L). TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment for insulin resistance; HbA1c, hemoglobin A1c; CRP, C-reactive protein; IL-6, interleukin 6; WC, waist circumference; ALT, alanine transaminase; AST, aspartate transaminase; SBP, systolic blood pressure; DBP, diastolic blood pressure; CI, confidence interval, weighted mean difference; WMD.

0.001) and > 1 g/d (WMD = −20.90 g/d; 95%CI, −23.87 to −17.93; P < 0.001), overweight (25–29.9 kg/m²) (WMD = −20.42; 95%CI, −23.52 to −17.31; P < 0.001), obese (>30 kg/m²) (WMD = −20.20 mg/dl; 95%CI, −30.23 to −10.16; P < 0.001), dyslipidemia (WMD = −35.00 mg/dl; 95%CI, −56.05 mg/dl to −13.94; P = 0.001), type 2 diabetes (WMD = −22.20; 95%CI, −26.87 to −17.54; P < 0.001), metabolic syndrome (WMD = −20.85; 95%CI, −29.47 to −12.22; P < 0.001), non-alcoholic fatty liver diseases (WMD = −18.24; 95%CI, −24.71 to −11.78; P < 0.001), other health status (WMD = −35.00; 95%CI, −56.05 to −13.94; P = 0.001), overweight (25–29.9 kg/m²) (WMD = −13.15; 95%CI, −18.75 to −7.55; P < 0.001), other health status (WMD = −13.15; 95%CI, −18.75 to −7.55; P < 0.001), and category of risk of bias of trails, high risk of bias (WMD = −20.59; 95%CI, −24.17 to 0.001), other health status (WMD = −13.10; 95%CI, −22.05 to −4.15; P = 0.004), and category of risk of bias of trails, high risk of bias (WMD = −24.07; 95%CI, −28.25 to −19.88; P < 0.001) (Table 3). Between study heterogeneity was found for TC (I² = 85.4%). The heterogeneity diminished when subgroup analysis was conducted on health status (metabolic syndrome) (I² = 0.00%, P = 0.807) (Table 3).

Effect of BBR supplementation on LDL

A total of 35 effect sizes from 35 studies were included in the meta-analysis of the effect of BBR supplementation on LDL (Figure 2C) (36, 37, 40–42, 44, 47–50, 52–56, 58–61, 63, 65–67, 71, 72, 74–76, 78–81, 84). BBR significantly reduced LDL compared to placebo (WMD = −9.63 mg/dl; 95%CI, −13.87 to −5.39; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on LDL was significant in studies conducted on the baseline LDL ≥ 100 mg/dl (WMD = −10.34 mg/dl; 95%CI, −14.82 to −5.86; P < 0.001), trial duration <8 weeks (WMD = −11.78; 95%CI, −17.74 to −5.81; P < 0.001), trial duration > 8 weeks (WMD = −8.79; 95%CI, −13.74 to −3.84; P < 0.001), intervention dose ≤1 g/d (WMD = −13.15 g/dl; 95%CI, −19.36 to −6.94; P < 0.001), and >1 g/d (WMD = −6.39; 95%CI, −11.47 to −1.30; P = 0.014), overweight (25–29.9 kg/m²) (WMD = −13.15; 95%CI, −18.75 to −7.55; P < 0.001), dyslipidemia (WMD = −17.92; 95%CI, −28.35 to −7.48;
| References                  | Random sequence generation | Allocation concealment | Selective reporting | Other sources of bias | Blinding (participants and personnel) | Blinding (outcome assessment) | Incomplete outcome data | General risk of bias |
|----------------------------|----------------------------|------------------------|---------------------|-----------------------|---------------------------------------|----------------------------|------------------------|----------------------|
| Kong et al. (52)           | U                         | H                      | L                   | H                     | H                                    | H                         | L                      | High                 |
| Wu et al. (73)             | U                         | H                      | L                   | H                     | H                                    | H                         | L                      | High                 |
| Zhang et al. (76)          | L                         | L                      | H                   | H                     | H                                    | L                         | U                      | Moderate             |
| Yin et al. (76)            | U                         | H                      | H                   | H                     | H                                    | H                         | H                      | High                 |
| Kong et al. (66)           | U                         | H                      | L                   | H                     | H                                    | H                         | L                      | High                 |
| Zhao et al. (80)           | L                         | H                      | L                   | H                     | L                                    | H                         | L                      | High                 |
| Ebrahim-Mamaghani et al. (44) | L                         | L                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Golzarand et al. (83)      | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |
| Gu et al. (47)             | L                         | H                      | H                   | H                     | H                                    | L                         | U                      | High                 |
| Zhang et al. (77)          | U                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Wei et al. (72)            | L                         | H                      | L                   | H                     | H                                    | H                         | L                      | High                 |
| Meng et al. (59)           | L                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Shadfar et al. (67)        | L                         | H                      | H                   | L                     | L                                    | U                         | L                      | Moderate             |
| Yan et al. (74)            | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |
| Derosa et al. (64)         | L                         | L                      | H                   | H                     | L                                    | U                         | L                      | Moderate             |
| Cheng et al. (42)          | U                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Pérez-Rubio et al. (62)    | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |
| Kashkooli et al. (50)      | L                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| An et al. (36)             | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |
| Zilaee et al. (81)         | L                         | L                      | L                   | H                     | L                                    | U                         | L                      | Low                  |
| Fei-qi et al. (46)         | L                         | H                      | L                   | H                     | L                                    | H                         | L                      | High                 |
| Dai et al. (43)            | L                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Yan et al. (75)            | L                         | H                      | H                   | H                     | H                                    | L                         | H                      | High                 |
| Zilaee et al. (62)         | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |
| Kashkooli et al. (50)      | U                         | H                      | H                   | H                     | H                                    | L                         | L                      | High                 |
| Lazavi et al. (85)         | L                         | H                      | H                   | L                     | H                                    | L                         | L                      | High                 |
| Chang et al. (41)          | L                         | H                      | L                   | L                     | H                                    | L                         | L                      | High                 |
| Guarino et al. (48)        | L                         | H                      | H                   | H                     | L                                    | U                         | L                      | High                 |

(Continued)
| References                  | Random sequence generation | Allocation concealment | Selective reporting | Other sources of bias | Blinding (participants and personnel) | Blinding (outcome assessment) | Incomplete outcome data | General risk of bias |
|----------------------------|-----------------------------|------------------------|---------------------|-----------------------|---------------------------------------|-----------------------------|------------------------|----------------------|
| Mansouri et al. (57)       | L                           | H                      | H                   | H                     | H                                     | H                          | L                      | High                 |
| Sharma et al. (66)         | L                           | L                      | H                   | H                     | H                                     | H                          | L                      | High                 |
| Asemani et al. (58)        | L                           | L                      | H                   | L                     | L                                     | L                          | L                      | Low                  |
| Rashidi et al. (63)        | L                           | H                      | H                   | H                     | L                                     | U                          | L                      | High                 |
| Lazavi et al. (54)         | L                           | L                      | H                   | L                     | L                                     | L                          | L                      | High                 |
| Tahmasebi et al. (70)      | L                           | L                      | H                   | H                     | L                                     | U                          | L                      | Moderate             |
| Cao et al. (39)            | U                           | H                      | H                   | H                     | H                                     | H                          | L                      | High                 |
| Aryaeian et al. (37)       | L                           | L                      | H                   | L                     | L                                     | U                          | L                      | Low                  |
| Sanjari et al. (65)        | L                           | H                      | H                   | H                     | L                                     | L                          | L                      | High                 |
| Soltani et al. (69)        | L                           | L                      | H                   | H                     | H                                     | H                          | L                      | High                 |
| Khorshidi-Sedehi et al. (53)| L                           | L                      | L                   | L                     | L                                     | U                          | L                      | Low                  |
| Li et al. (56)             | L                           | L                      | H                   | H                     | L                                     | U                          | L                      | Low                  |
| Emamat et al. (45)         | L                           | L                      | H                   | H                     | H                                     | H                          | L                      | High                 |
| León-Martínez et al. (55)  | L                           | L                      | H                   | H                     | L                                     | U                          | L                      | Moderate             |
| Memon et al. (58)          | U                           | H                      | H                   | H                     | L                                     | H                          | L                      | High                 |
| Zhao et al. (86)           | L                           | L                      | H                   | H                     | L                                     | U                          | L                      | Moderate             |
| Harrison et al. (49)       | L                           | L                      | H                   | H                     | L                                     | U                          | H                      | High                 |
| Chan et al. (40)           | L                           | L                      | H                   | H                     | L                                     | U                          | H                      | High                 |
| Wang et al. (71)           | L                           | L                      | H                   | H                     | L                                     | U                          | H                      | High                 |
| Nejati et al. (61)         | L                           | L                      | H                   | H                     | L                                     | L                          | L                      | High                 |
| Mishra et al. (60)         | L                           | L                      | H                   | H                     | L                                     | L                          | L                      | High                 |

General low risk < 2 high risk.
General moderate risk = 2 high risk.
General high risk > 2 high risk.
### TABLE 3  Subgroup analyses of berberine supplementation on cardiovascular risk factors in adults.

| Subgroup analyses of berberine on serum TG (mg/dl) | No | WMD (95%CI) | P-value | Heterogeneity |
|---------------------------------------------------|----|-------------|---------|--------------|
|                                                   |    |             |         | P between sub-groups |
|                                                   |    |             |         | t² | P |
| Overall effect                                     | 38 | -23.70 (−30.16, −17.25) | <0.001 | <0.001 | 96.6% |
| Baseline TG (mg/dl)                                |    |             |         |         |     |
| <150                                              | 7  | -18.18 (−23.63, −12.73) | <0.001 | <0.238 | 25.0% | 0.083 |
| ≥150                                              | 31 | -26.34 (−33.78, −18.90) | <0.001 | <0.001 | 97.1% |
| Trial duration (week)                              |    |             |         |         |     |
| ≤8                                                | 11 | -20.94 (−30.70, −11.17) | <0.001 | 0.022  | 52.0% | 0.464 |
| >8                                                 | 27 | -25.59 (−33.31, −17.86) | <0.001 | <0.001 | 97.5% |
| Intervention dose (g/day)                          |    |             |         |         |     |
| ≤1                                                | 18 | -24.96 (−38.79, −11.13) | <0.001 | <0.001 | 91.5% | 0.994 |
| >1                                                 | 20 | -24.89 (−32.93, −16.86) | <0.001 | <0.001 | 97.8% |
| Baseline BMI (kg/m²)                               |    |             |         |         |     |
| Normal (18.5–24.9)                                 | 5  | -4.47 (−35.76, −26.82) | 0.779  | <0.001 | 96.5% | 0.371 |
| Overweight (25–29.9)                               | 18 | -26.88 (−36.98, −16.78) | <0.001 | <0.001 | 96.6% |
| Obese (>30)                                        | 7  | -28.93 (−44.38, −13.48) | <0.001 | <0.001 | 80.9% |
| Health status                                      |    |             |         |         |     |
| Dyslipidemia                                       | 5  | -26.53 (−47.04, −6.02) | 0.011  | 0.286  | 20.2% | <0.001 |
| Type 2 diabetes                                    | 15 | -26.40 (−33.91, −18.89) | <0.001 | <0.001 | 94.7% |
| Metabolic syndrome                                 | 4  | -32.17 (−59.74, −4.60) | 0.022  | <0.001 | 75.9% |
| Nonalcoholic fatty liver disease                   | 5  | -32.30 (−54.36, −10.24) | 0.004  | <0.001 | 86.5% |
| Others                                             | 9  | -8.41 (−22.52, 5.68)    | 0.242  | <0.001 | 93.8% |
| Risk of bias                                       |    |             |         |         |     |
| High                                               | 30 | -24.40 (−33.14, −15.66) | <0.001 | <0.001 | 97.2% | 0.102 |
| Moderate                                           | 5  | -27.55 (−38.65, −16.46) | <0.001 | <0.001 | 90.0% |
| Low                                                | 3  | -8.79 (−22.98, 5.40)    | 0.225  | 0.668  | 0.0%  |
| Subgroup analyses of berberine on serum TC (mg/dl) |    |             |         |         |     |
| Overall effect                                     | 34 | -20.64 (−23.65, −17.63) | <0.001 | <0.001 | 85.4% |
| Baseline TC (mg/dl)                                |    |             |         |         |     |
| <200                                               | 10 | -12.10 (−18.86, −5.34) | <0.001 | <0.001 | 78.0% | 0.003 |
| ≥200                                               | 24 | -23.81 (−27.55, 20.06) | 0.035  | <0.001 | 86.2% |
| Trial duration (week)                              |    |             |         |         |     |
| ≤8                                                 | 10 | -18.09 (−26.21, −9.97) | <0.001 | <0.001 | 77.7% | 0.475 |
| >8                                                 | 24 | -21.30 (−24.74, 17.86) | <0.001 | <0.001 | 87.3% |
| Intervention dose (g/day)                          |    |             |         |         |     |
| ≤1                                                 | 16 | -21.30 (−28.23, −14.36) | <0.001 | <0.001 | 90.7% | 0.918 |
| >1                                                 | 18 | -20.90 (−23.87, −17.93) | <0.001 | <0.001 | 73.9% |
| Baseline BMI (kg/m²)                               |    |             |         |         |     |
| Normal (18.5–24.9)                                 | 5  | -10.58 (−30.39, 9.23) | 0.295  | <0.001 | 95.3% | 0.630 |
| Overweight (25–29.9)                               | 18 | -20.42 (−23.52, −17.31) | <0.001 | <0.001 | 72.8% |
| Obese (>30)                                        | 4  | -20.20 (−30.23, −10.16) | <0.001 | 0.005  | 77.0% |
| Health status                                      |    |             |         |         |     |
| Dyslipidemia                                       | 5  | -35.00 (−56.05, −13.94) | 0.001  | <0.001 | 86.8% | <0.001 |
| Type 2 diabetes                                    | 12 | -22.20 (−26.87, −17.54) | <0.001 | <0.001 | 78.0% |
| Metabolic syndrome                                 | 3  | -26.85 (−29.47, −24.22) | <0.001 | 0.807  | 0.000 |
| Nonalcoholic fatty liver disease                   | 5  | -18.24 (−24.71, −11.78) | <0.001 | 0.017  | 66.9% |

(Continued)
### TABLE 3 (Continued)

| Risk of bias | No | WMD (95%CI) | P-value | Heterogeneity |
|--------------|----|-------------|---------|---------------|
|              |    |             |         |               |
| Others       | 9  | −13.10 (−22.05, −4.15) | 0.004   | <0.001        | 92.0% |
| Risk of bias |    |             |         |               |
| High         | 26 | −20.59 (−24.59, −16.58) | <0.001  | <0.001        | 87.5% | 0.265 |
| Moderate     | 5  | −24.07 (−28.25, −19.88) | <0.001  | 0.019         | 66.2% |
| Low          | 3  | −13.25 (−28.64, 2.13)   | 0.091   | 0.013         | 77.1% |
| Subgroup analyses of berberine on serum LDL (mg/dl) |    |             |         |               |
| Overall effect | 35 | −9.63 (−13.87, −5.39)   | <0.001  | <0.001        | 96.1% |
| Baseline LDL (mg/dl) |    |             |         |               |
| <100         | 4  | −3.31 (−13.33, 6.69)    | 0.516   | 0.075         | 56.6% | 0.209 |
| ≥100         | 31 | −10.34 (−14.82, −5.86)  | <0.001  | <0.001        | 96.5% |
| Trial duration (week) |    |             |         |               |
| ≤8           | 9  | −11.78 (−17.74, −5.81)  | <0.001  | 0.006         | 62.7% | 0.450 |
| >8           | 26 | −8.79 (−13.74, −3.84)   | <0.001  | <0.001        | 97.1% |
| Intervention dose (g/day) |    |             |         |               |
| ≤1           | 17 | −13.15 (−19.36, −6.94)  | <0.001  | <0.001        | 92.3% | 0.099 |
| >1           | 18 | −6.39 (−11.47, −1.30)   | 0.014   | <0.001        | 95.6% |
| Baseline BMI (kg/m²) |    |             |         |               |
| Normal (18.5–24.9) | 5  | −6.76 (−20.53, 6.99)    | 0.335   | <0.001        | 95.1% | 0.454 |
| Overweight (25–29.9) | 18 | −13.15 (−18.75, −7.55) | <0.001  | <0.001        | 95.5% |
| Obese (>30)  | 6  | 1.11 (−26.48, 28.70)    | 0.937   | <0.001        | 98.4% |
| Health status |    |             |         |               |
| Dyslipidemia | 5  | −17.92 (−28.35, −7.48)  | 0.001   | 0.065         | 54.9% | 0.001 |
| Type 2 diabetes | 14 | −5.42 (−12.79, 1.95)    | 0.150   | <0.001        | 96.7% |
| Metabolic Syndrome | 2  | −22.30 (−30.90, −13.71) | <0.001  | 0.348         | 0.00% |
| Nonalcoholic fatty liver disease | 5  | −6.50 (−7.72, −5.29)    | <0.001  | 0.883         | 0.00% |
| Others       | 9  | −11.69 (−21.17, −2.20)  | 0.016   | <0.001        | 95.6% |
| Risk of bias |    |             |         |               |
| High         | 27 | −7.20 (−11.51, −2.89)   | 0.001   | <0.001        | 94.2% | 0.004 |
| Moderate     | 5  | −19.20 (−24.90, −13.50) | <0.001  | <0.001        | 85.6% |
| Low          | 3  | −14.55 (−22.47, −6.64)  | <0.001  | 0.187         | 40.4% |
| Subgroup analyses of berberine on serum HDL (mg/dl) |    |             |         |               |
| Overall effect | 34 | 1.37 (0.41, 2.33)      | 0.005   | <0.001        | 92.7% |
| Baseline HDL (mg/dl) |    |             |         |               |
| <40          | 8  | 1.17 (0.08, 2.27)       | 0.035   | <0.001        | 89.6% | 0.960 |
| ≥40          | 26 | 1.22 (−0.18, 2.63)      | 0.088   | <0.001        | 90.6% |
| Trial duration (week) |    |             |         |               |
| ≤8           | 9  | 2.17 (0.10, 4.23)       | 0.039   | <0.001        | 77.3% | 0.371 |
| >8           | 25 | 1.10 (−0.02, 2.22)      | 0.055   | <0.001        | 94.2% |
| Intervention dose (g/day) |    |             |         |               |
| ≤1           | 16 | 0.49 (−1.86, 2.85)      | 0.682   | <0.001        | 92.2% | 0.307 |
| >1           | 18 | 1.81 (0.88, 2.75)       | <0.001  | <0.001        | 90.1% |
| Baseline BMI (kg/m²) |    |             |         |               |
| Normal (18.5–24.9) | 5  | −1.34 (−6.07, 3.39)    | 0.579   | <0.001        | 94.9% | 0.048 |
| Overweight (25–29.9) | 18 | 0.91 (0.04, 1.78)      | 0.039   | <0.001        | 78.3% |
| Obese (>30)  | 5  | 4.85 (1.52, 8.17)      | 0.004   | <0.001        | 88.5% |
| Health status                          | No | WMD (95%CI)     | P-value | Heterogeneity |
|---------------------------------------|----|-----------------|---------|---------------|
|                                       |    |                 |         | P heterogeneity | I² | P between sub-groups |
| Dyslipidemia                          | 5  | $-1.96 \, (\text{-6.85, 2.92})$ | 0.430   | 0.104 | 47.9% | 0.004 |
| Type 2 diabetes                       | 14 | 1.65 \, (0.19, 3.10) | 0.026   | <0.001 | 93.4% |
| Metabolic Syndrome                    | 2  | 6.90 \, (2.42, 11.37) | 0.002   | 0.078 | 60.8% |
| Nonalcoholic fatty liver disease      | 5  | $-0.00 \, (\text{-0.22, 0.20})$ | 0.957   | 0.988 | 0.00%  |
| Others                                | 9  | 1.03 \, (1.26, 3.34) | 0.377   | <0.001 | 91.3%  |
| Risk of bias                          |    |                 |         |         |       |       |
| High                                  | 26 | 1.22 \, (0.08, 2.36) | 0.035   | <0.001 | 93.9%  | 0.106 |
| Moderate                              | 5  | 0.30 \, (1.35, 1.97) | 0.718   | 0.009 | 70.6%  |
| Low                                   | 3  | 5.46 \, (0.93, 9.99) | 0.018   | 0.042 | 68.5%  |

Subgroup analyses of berberine on serum FBG (mg/dl)

| Overall effect     | 35 | $-7.74 \, (\text{-10.79, -4.70})$ | <0.001 | <0.001 | 97.0% |
| Baseline BMI (kg/m²) |    |                 |         |         |       |       |
| Normal (18.5–24.9) | 6  | $-3.44 \, (\text{-5.75, -1.13})$ | 0.003  | 0.089 | 47.6% | 0.003 |
| Overweight (25–29.9) | 18 | $-9.21 \, (\text{-12.90, -5.52})$ | <0.001 | <0.001 | 96.4% |
| Obese (>30)        | 4  | $-0.17 \, (\text{-3.96, 3.62})$ | 0.930  | 0.322 | 14.0% |

Health status

| Diabetes            | 15 | $-16.84 \, (\text{-24.51, -9.17})$ | <0.001 | <0.001 | 94.5% |
| Metabolic syndrome  | 4  | 6.85 \, (2.46, 16.16) | 0.150   | <0.001 | 89.0% |
| Nonalcoholic fatty liver disease | 5  | $-2.21 \, (\text{-4.41, -0.02})$ | 0.048   | 0.004 | 73.9% |
| Others              | 10 | $-2.80 \, (\text{-5.92, 0.32})$ | 0.079   | <0.001 | 86.9% |

Risk of bias

| High     | 27 | $-6.76 \, (\text{-10.61, -2.90})$ | 0.001   | <0.001 | 96.6% | 0.623 |
| Moderate | 5  | $-13.56 \, (\text{-26.81, -0.31})$ | 0.045   | <0.001 | 98.7% |
| Low      | 3  | $-6.58 \, (\text{-19.31, 6.14})$ | 0.311   | <0.001 | 94.6% |

Subgroup analyses of berberine on serum Insulin (mg/dl)

| Overall effect | 16 | $-3.27 \, (\text{-4.46, -2.07})$ | <0.001 | <0.001 | 95.3% |
| Trial duration (week) |    |                 |         |         |       |       |
| ≤8              | 6  | $-3.74 \, (\text{-4.65, -1.84})$ | 0.007  | <0.001 | 96.2% | 0.777 |
| >8              | 10 | $-3.28 \, (\text{-5.01, -1.54})$ | <0.001 | <0.001 | 93.7% |

| Intervention dose (g/day) |    |                 |         |         |       |       |
| ≤1              | 14 | $-4.73 \, (\text{-8.75, -0.71})$ | 0.021  | <0.001 | 89.5% | 0.116 |
| >1              | 21 | $-9.88 \, (\text{-14.88, -4.88})$ | <0.001 | <0.001 | 98.0% |

| Trial duration (week) |    |                 |         |         |       |       |
| ≤8              | 6  | $-3.74 \, (\text{-4.65, -1.84})$ | 0.007  | <0.001 | 96.2% | 0.777 |
| >8              | 10 | $-3.28 \, (\text{-5.01, -1.54})$ | <0.001 | <0.001 | 93.7% |

| Intervention dose (g/day) |    |                 |         |         |       |       |
| ≤1              | 14 | $-4.73 \, (\text{-8.75, -0.71})$ | 0.021  | <0.001 | 89.5% | 0.116 |
| >1              | 21 | $-9.88 \, (\text{-14.88, -4.88})$ | <0.001 | <0.001 | 98.0% |

| Trial duration (week) |    |                 |         |         |       |       |
| ≤8              | 6  | $-3.74 \, (\text{-4.65, -1.84})$ | 0.007  | <0.001 | 96.2% | 0.777 |
| >8              | 10 | $-3.28 \, (\text{-5.01, -1.54})$ | <0.001 | <0.001 | 93.7% |

| Intervention dose (g/day) |    |                 |         |         |       |       |
| ≤1              | 14 | $-4.73 \, (\text{-8.75, -0.71})$ | 0.021  | <0.001 | 89.5% | 0.116 |
| >1              | 21 | $-9.88 \, (\text{-14.88, -4.88})$ | <0.001 | <0.001 | 98.0% |

(Continued)
TABLE 3 (Continued)

|                          | No  | WMD (95%CI)      | P-value | Heterogeneity |
|--------------------------|-----|------------------|---------|---------------|
|                          |     |                  |         | P heterogeneity | I²     | P between sub-groups |
| Health status            |     |                  |         |               |        |                      |
| Overweight (25–29.9)     | 11  | −4.11 (−5.87, −2.35) | <0.001  | <0.001        | 90.9% |
| Obese (>30)              | 1   | −2.98 (−4.66, −1.29) | 0.001   | −            | −     |
| Risk of bias             |     |                  |         |               |        |                      |
| High                     | 12  | −4.34 (−6.50, −2.17) | <0.001  | <0.001        | 94.8% |
| Moderate                 | 2   | −1.90 (−2.42, −1.38) | <0.001  | 0.928         | 0.0%  |
| Low                      | 2   | −1.15 (−3.57, 1.25)  | 0.346   | 0.010         | 85.0% |
| Subgroup analyses of berberine on serum HbA1c (%) |     |                  |         |               |        |                      |
| Overall effect           | 21  | −0.45 (−0.68, −0.23) | <0.001  | <0.001        | 92.5% |
| Trial duration (week)    |     |                  |         |               |        |                      |
| ≤8                       | 5   | 0.12 (−0.47, 0.73)   | 0.680   | <0.001        | 83.2% |
| >8                       | 16  | −0.61 (−0.85, −0.22) | <0.001  | <0.001        | 93.2% |
| Intervention dose (g/day)|     |                  |         |               |        |                      |
| ≤1                       | 10  | −0.21 (−0.67, 0.25)  | 0.374   | <0.001        | 94.3% |
| >1                       | 11  | −0.64 (−0.92, −0.37) | <0.001  | <0.001        | 87.4% |
| Baseline BMI (kg/m²)     |     |                  |         |               |        |                      |
| Normal (18.5–24.9)       | 2   | 0.53 (0.28, 0.79)    | <0.001  | 0.909         | 0.0%  |
| Overweight (25–29.9)     | 13  | −0.41 (−0.53, −0.29) | <0.001  | 0.057         | 41.6% |
| Obese (>30)              | 4   | −0.94 (−1.36, −0.53) | <0.001  | 0.003         | 78.8% |
| Health status            |     |                  |         |               |        |                      |
| Type 2 diabetes          | 8   | −3.35 (−4.98, −1.72) | <0.001  | <0.001        | 87.3% |
| Metabolic syndrome       | 1   | −7.30 (−16.96, 2.36) | 0.139   | −            | −     |
| Non-alcoholic fatty liver disease | 2   | −6.09 (−16.74, 4.54) | 0.261   | <0.001        | 98.1% |
| Others                   | 5   | −2.08 (−3.74, −0.42) | 0.014   | <0.001        | 94.6% |

Subgroup analyses of berberine on HOMA-IR

|                          | No  | WMD (95%CI)      | P-value | Heterogeneity |
|--------------------------|-----|------------------|---------|---------------|
|                          |     |                  |         | P heterogeneity | I²     | P between sub-groups |
| Health status            |     |                  |         |               |        |                      |
| Overweight (25–29.9)     | 11  | −4.11 (−5.87, −2.35) | <0.001  | <0.001        | 90.9% |
| Obese (>30)              | 1   | −2.98 (−4.66, −1.29) | 0.001   | −            | −     |
| Risk of bias             |     |                  |         |               |        |                      |
| High                     | 12  | −4.34 (−6.50, −2.17) | <0.001  | <0.001        | 94.8% |
| Moderate                 | 2   | −1.90 (−2.42, −1.38) | <0.001  | 0.928         | 0.0%  |
| Low                      | 2   | −1.15 (−3.57, 1.25)  | 0.346   | 0.010         | 85.0% |

(Continued)
| Table 3 (Continued) | No | WMD (95%CI) | P-value | Heterogeneity |
|----------------------|----|-------------|---------|---------------|
|                       |    |             | P       | I²             | P between sub-groups |
|                       |    |             | heterogeneity |               |               |
| Nondiabetic fatty liver disease | 2  | −0.68 (−1.12, −0.23) | 0.003 | 0.518 | 0.0% |
| Others                | 5  | −0.62 (−1.24, −0.00) | 0.047 | <0.001 | 87.6% |
| Risk of bias          |    |             |         |               |               |
| High                  | 10 | −1.12 (−1.59, −0.65) | <0.001 | <0.001 | 85.6% 0.011 |
| Moderate              | 2  | −1.10 (−1.18, −1.02) | <0.001 | 0.498 | 0.0% |
| Low                   | 2  | −0.25 (−0.80, 0.30)  | 0.374  | 0.012 | 84.2% |
| Subgroup analyses of berberine on SBP (mmHg) |  |             |         |               |               |
| Overall effect        | 20 | −5.46 (−8.17, −2.76) | <0.001 | <0.001 | 86.3% |
| Baseline SBP (mmHg)   |    |             |         |               |               |
| <120                  | 13 | −2.93 (−4.09, −1.76) | <0.001 | 0.480 | 0.0% 0.028 |
| ≥120                  | 7  | −10.29 (−16.75, −3.82) | 0.002 | <0.001 | 91.7% |
| Trial duration (week) |    |             |         |               |               |
| ≤8                    | 8  | −6.83 (−11.98, −1.68) | 0.009  | <0.001 | 85.2% 0.491 |
| >8                    | 12 | −4.68 (−7.99, −1.36)  | 0.006  | <0.001 | 87.9% |
| Intervention dose (g/day) |    |             |         |               |               |
| ≤1                    | 11 | −3.85 (−7.50, −0.19)  | 0.039  | <0.001 | 88.9% 0.190 |
| >1                    | 9  | −7.58 (−11.79, −3.36) | <0.001 | <0.001 | 82.8% |
| Baseline BMI (kg/m²)  |    |             |         |               |               |
| Normal (18.5–24.9)    | 2  | −2.12 (−5.52, 1.28)   | 0.223  | 0.363 | 0.0% 0.089 |
| Overweight (25–29.9)  | 12 | −5.20 (−8.48, −1.92)  | 0.002  | <0.001 | 79.5% |
| Obese (>30)           | 4  | −9.69 (−15.77, −3.60) | 0.002  | <0.001 | 90.1% |
| Health status         |    |             |         |               |               |
| Dyslipidemia          | 2  | −1.33 (−4.64, 1.97)   | 0.428  | 0.779 | 0.0% 0.034 |
| Type 2 diabetes       | 12 | −6.99 (−11.29, −2.68) | 0.001  | <0.001 | 89.9% |
| Metabolic syndrome    | 2  | −5.70 (−8.49, −2.91)  | <0.001 | 0.839 | 0.0% |
| Non-alcoholic fatty liver disease | 1 | −0.85 (−3.50, 1.80)   | 0.530  | – | – |
| Others                | 3  | −3.76 (−6.97, −0.55)  | 0.022  | 0.281 | 21.1% |
| Risk of bias          |    |             |         |               |               |
| High                  | 15 | −6.73 (−10.19, −3.27) | <0.001 | <0.001 | 88.4% 0.057 |
| Moderate              | 4  | −2.27 (−4.33, −0.21)  | 0.030  | 0.667 | 0.0% |
| Subgroup analyses of berberine on DBP (mmHg) |  |             |         |               |               |
| Overall effect        | 20 | −2.74 (−5.63, 0.15)   | 0.063  | <0.001 | 94.9% |
| Baseline DBP (mmHg)   |    |             |         |               |               |
| <80                   | 9  | −0.85 (−3.44, 1.72)   | 0.516  | <0.001 | 84.1% 0.193 |
| ≥80                   | 11 | −4.20 (−8.52, 0.12)   | 0.057  | <0.001 | 95.9% |
| Trial duration (week) |    |             |         |               |               |
| ≤8                    | 8  | −3.12 (−5.47, −0.77)  | 0.009  | 0.002 | 70.0% 0.811 |
| >8                    | 12 | −2.52 (−6.88, 1.84)   | 0.257  | <0.001 | 96.8% |
| Intervention dose (g/day) |    |             |         |               |               |
| ≤1                    | 11 | −2.46 (−6.86, 1.93)   | 0.273  | <0.001 | 97.2% 0.840 |
| >1                    | 9  | −2.95 (−4.90, −1.00)  | 0.003  | 0.037 | 51.2% |
| Baseline BMI (kg/m²)  |    |             |         |               |               |
| Normal (18.5–24.9)    | 2  | −1.24 (−3.31, 0.82)   | 0.237  | 0.628 | 0.0% 0.359 |
| Overweight (25–29.9)  | 12 | −1.61 (−4.10, 0.87)   | 0.204  | <0.001 | 84.2% |
| Obese (>30)           | 4  | −7.40 (−15.58, 0.76)  | 0.076  | <0.001 | 97.5% |

(Continued)
TABLE 3 (Continued)

| Health status                          | No | WMD (95%CI)          | P-value | Heterogeneity |
|----------------------------------------|----|----------------------|---------|---------------|
|                                        |    |                      |         | I²            | P between sub-groups |
| [P value] Heterogeneity I² P between sub-groups |
| Health status                          |    |                      |         |               |                          |
| Dyslipidemia                           | 2  | −1.66 (−4.76, 1.42)  | 0.290   | 0.276         | 15.7%                    | 0.002                     |
| Type 2 diabetes                        | 12 | −2.70 (−7.38, 1.98)  | 0.258   | <0.001        | 96.7%                    |                           |
| Metabolic Syndrome                     | 2  | −5.18 (−6.91, −3.45) | <0.001  | 0.502         | 0.0%                     |                           |
| Nonalcoholic fatty liver disease       | 1  | 0.13 (−1.72, 1.98)   | 0.891   | –             | –                        |                           |
| Others                                 | 3  | −2.88 (−8.67, 2.90)  | 0.328   | 0.001         | 86.0%                    |                           |
| Risk of bias                           |    |                      |         |               |                          |                           |
| High                                   | 15 | −3.30 (−7.01, 0.39)  | 0.080   | <0.001        | 96.0%                    | 0.203                     |
| Moderate                               | 4  | −1.21 (−2.70, 0.26)  | 0.108   | 0.734         | 0.0%                     |                           |
| Subgroup analyses of berberine on serum CRP (mg/l) |
| Overall effect                         | 9  | 0.05 (−0.59, 0.68)   | 0.887   | <0.001        | 97.4%                    |                           |
| Trial duration (week)                  |    |                      |         |               |                          |                           |
| ≤8                                     | 5  | 0.53 (−0.45, 1.51)   | 0.290   | <0.001        | 97.6%                    | 0.044                     |
| >8                                     | 4  | −1.19 (−2.55, 0.16)  | 0.085   | 0.034         | 65.4%                    |                           |
| Intervention dose (g/day)              |    |                      |         |               |                          |                           |
| ≤1                                     | 4  | −0.56 (−0.87, −0.25) | <0.001  | 0.004         | 77.4%                    | 0.391                     |
| >1                                     | 5  | 0.24 (−1.59, 2.08)   | 0.791   | <0.001        | 97.0%                    |                           |
| Baseline BMI (kg/m²)                   |    |                      |         |               |                          |                           |
| Normal (18.5–24.9)                     | 3  | −0.26 (−0.73, 0.20)  | 0.269   | <0.001        | 96.9%                    | 0.151                     |
| Overweight (25–29.9)                   | 3  | −1.47 (−4.23, 1.27)  | 0.293   | <0.001        | 87.3%                    |                           |
| Obese (>30)                            | 1  | −1.06 (−1.77, −0.34) | 0.003   | –             | –                        |                           |
| Health status                          |    |                      |         |               |                          |                           |
| Type 2 diabetes                        | 3  | −0.26 (−1.31, 0.78)  | 0.621   | 0.003         | 82.5%                    | 0.838                     |
| Metabolic Syndrome                     | 2  | 0.97 (−3.00, 4.95)   | 0.630   | <0.001        | 98.8%                    |                           |
| Others                                 | 4  | −0.15 (−0.65, 0.33)  | 0.531   | 0.002         | 79.8%                    |                           |
| Risk of bias                           |    |                      |         |               |                          |                           |
| High                                   | 6  | 0.51 (−0.21, 1.24)   | 0.167   | <0.001        | 98.3%                    | 0.053                     |
| Low                                    | 2  | −4.29 (−11.56, 2.97) | 0.247   | 0.008         | 85.9%                    |                           |
| Subgroup analyses of berberine on serum IL-6 (ng/l) |
| Overall effect                         | 4  | −0.53 (−1.11, 0.05)  | 0.073   | <0.001        | 94.7%                    |                           |
| Trial duration (week)                  |    |                      |         |               |                          |                           |
| ≤8                                     | 3  | −0.56 (−1.21, 0.08)  | 0.087   | <0.001        | 96.4%                    | 0.790                     |
| >8                                     | 1  | −0.40 (−1.43, 0.63)  | 0.448   | –             | –                        |                           |
| Intervention dose (g/day)              |    |                      |         |               |                          |                           |
| ≤1                                     | 2  | −0.55 (−0.74, −0.36) | <0.001  | 0.766         | 0.0%                     | 0.634                     |
| >1                                     | 2  | −1.21 (−3.93, 1.50)  | 0.380   | <0.001        | 92.5%                    |                           |
| Baseline BMI (kg/m²)                   |    |                      |         |               |                          |                           |
| Normal (18.5–24.9)                     | 1  | −0.56 (−0.75, −0.37) | <0.001  | –             | –                        | 0.422                     |
| Overweight (25–29.9)                   | 2  | −1.49 (−3.75, 0.77)  | 0.196   | 0.013         | 83.9%                    |                           |
| Subgroup analyses of berberine on weight (kg) |
| Overall effect                         | 21 | −0.84 (−1.34, −0.34) | <0.001  | 0.187         | 21.2%                    |                           |
| Trial duration (week)                  |    |                      |         |               |                          |                           |
| ≤8                                     | 4  | −0.86 (−2.84, 1.11)  | 0.393   | 0.687         | 0.0%                     | 0.987                     |
| >8                                     | 17 | −0.87 (−1.44, −0.31) | 0.002   | 0.092         | 33.1%                    |                           |
### TABLE 3 (Continued)

| Subgroup analyses of berberine on BMI (kg/m²) |
|---------------------------------------------|
| Overall effect                              |
| ≤8                                         |
| 8                                          |
| 16                                         |
| Intervention dose (g/day)                   |
| ≤1                                         |
| 10                                         |
| >1                                         |
| Baseline BMI (kg/m²)                        |
| Normal (18.5–24.9)                         |
| 2                                          |
| Overweight (25–29.9)                       |
| 17                                         |
| Obese (>30)                                |
| 2                                          |
| Risk of bias                               |
| High                                       |
| Moderate                                   |
| Baseline BMI (kg/m²)                        |
| Normal (18.5–24.9)                         |
| 2                                          |
| Overweight (25–29.9)                       |
| 17                                         |
| Obese (>30)                                |
| 2                                          |
| Risk of bias                               |
| High                                       |
| Moderate                                   |
| Baseline BMI (kg/m²)                        |
| Normal (18.5–24.9)                         |
| 2                                          |
| Overweight (25–29.9)                       |
| 17                                         |
| Obese (>30)                                |
| 2                                          |
| Subgroup analyses of berberine on WC (cm)   |
| Overall effect                              |
| Intervention dose (g/day)                   |
| ≤1                                         |
| 4                                          |
| >1                                         |
| Baseline BMI (kg/m²)                        |
| Normal (18.5–24.9)                         |
| 2                                          |
| Overweight (25–29.9)                       |
| 7                                          |
| Obese (>30)                                |
| 2                                          |
| Risk of bias                               |
| High                                       |
| Moderate                                   |

(Continued)
TABLE 3 (Continued)

| Subgroup analyses of berberine on ALT (U/L) | No | WMD (95%CI) | P-value | Heterogeneity |
|-------------------------------------------|----|-------------|---------|---------------|
|                                           |    |             |         | P heterogeneity | I² | P between sub-groups |
| High                                      | 8  | −2.26 (−4.99, 0.45) | 0.103 | <0.001 | 94.5% | 0.104 |
| Moderate                                  | 2  | 0.39 (−0.03, 0.83)  | 0.073 | 0.912 | 0.0% | 0.148 |

| Trial duration (week)                     | 12 | −4.22 (−8.75, 0.31) | 0.068 | <0.001 | 92.3% |
| ≤8                                        | 2  | −0.53 (−2.57, 1.50)  | 0.606 | 0.433 | 0.0% | 0.0% |
| >8                                        | 10 | −5.34 (−11.53, 0.84) | 0.090 | <0.001 | 93.7% |

| Intervention dose (g/day)                 | 8  | −4.09 (−9.67, 1.49)  | 0.151 | <0.001 | 94.9% | 0.997 |
| ≤1                                        | 4  | −4.07 (−10.81, 2.67) | 0.237 | 0.121 | 48.4% |

| Baseline BMI (kg/m²)                      |    |             |         |             |     |      |
| Normal (18.5–24.9)                        | 1  | −4.70 (−11.24, 1.84) | 0.159 | – | – | 0.289 |
| Overweight (25–29.9)                      | 5  | 0.19 (−1.40, 1.79)   | 0.811 | 0.220 | 30.2% |
| Obese (>30)                               | 3  | −3.86 (−14.71, 6.99) | 0.485 | 0.066 | 63.2% |

| Health status                             |    |             |         |             |     |      |
| Dyslipidemia                              | 2  | −4.42 (−36.17, 27.32) | 0.785 | <0.001 | 95.3% | 0.859 |
| Type 2 diabetes                           | 4  | −1.60 (−5.27, 2.06)   | 0.393 | 0.155 | 42.8% |
| Nonalcoholic fatty liver disease          | 4  | −5.89 (−16.16, 4.38)  | 0.261 | <0.001 | 90.4% |
| Others                                    | 2  | −0.73 (−6.57, 5.09)   | 0.805 | 0.069 | 69.8% |

| Subgroup analyses of berberine on AST(U/L) |    |             |         |             |     |      |
| Overall effect                            | 9  | −2.94 (−8.68, 2.81)  | 0.316 | <0.001 | 95.8% |
| Trial duration (week)                     | 12 | −4.22 (−8.75, 0.31) | 0.068 | <0.001 | 92.3% |
| ≤8                                        | 2  | −0.33 (−2.09, 1.42)  | 0.709 | 0.758 | 0.0% | 0.493 |
| >8                                        | 7  | −3.45 (−12.21, 5.30) | 0.439 | <0.001 | 96.8% |

| Intervention dose (g/day)                 | 6  | −3.51 (−12.14, 5.12) | 0.425 | <0.001 | 97.4% | 0.655 |
| ≤1                                        | 3  | −1.46 (−3.74, 0.82)  | 0.210 | 0.910 | 0.0% | 0.0% |

| Baseline BMI (kg/m²)                      |    |             |         |             |     |      |
| Overweight (25–29.9)                      | 5  | 0.24 (−1.83, 2.31)   | 0.821 | 0.063 | 55.3% | 0.620 |
| Obese (>30)                               | 1  | −0.90 (−4.90, 3.10)  | 0.660 | – | – | 0.0% |

| Health status                             |    |             |         |             |     |      |
| Dyslipidemia                              | 2  | 0.53 (−24.44, 25.52) | 0.966 | 0.002 | 89.9% | 0.084 |
| Type 2 diabetes                           | 2  | −0.20 (−2.14, 1.74)  | 0.839 | 0.992 | 0.0% | 0.0% |
| Nonalcoholic fatty liver disease          | 4  | −6.27 (−16.78, 4.22) | 0.242 | <0.001 | 96.9% |
| Others                                    | 1  | 2.50 (0.97, 4.03)    | 0.001 | – | – | 0.0% |

ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CI, confidence interval; CRP, c-reactive protein; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; DBP, diastolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WC, waist circumference; WMD, weighted mean differences; IL-6, Interleukin 6.

P = 0.001), metabolic syndrome (WMD = −22.30; 95%CI, −30.90 to −13.71; P < 0.001), non-alcoholic fatty liver disease (WMD = −6.50; 95%CI, −7.72 to −5.29; P < 0.001), other health status (WMD = −11.69; 95%CI, −21.17 to −2.20; P = 0.016), and category of risk of bias of trials, high risk of bias (WMD = −7.20; 95%CI −11.51 to −2.89; P = 0.001), moderate risk of bias (WMD = −19.20; 95%CI −24.90 to −13.50; P < 0.001), low risk of bias trials (WMD = −14.55; 95%CI −22.47 to −6.64; P < 0.001) (Table 3). Between study heterogeneity was found for LDL (I² = 96.1%). The heterogeneity disappeared when subgroup analysis was conducted on baseline LDL (<100) (I² = 56.6%, P = 0.075), health status including dyslipidemia (I² = 54.9%, P = 0.065), metabolic syndrome (I² = 0.00%, P = 0.348), and non-alcoholic fatty liver disease (I² = 0.00%, P
Effect of BBR supplementation on HDL

A total of 34 effect sizes from 34 studies were included in the meta-analysis of the effect of BBR supplementation on HDL (Figure 2D) (36, 37, 40–42, 44, 47, 48, 50, 52–56, 58–63, 65–67, 71, 72, 74–76, 78, 79, 81, 84). BBR supplementation significantly increased HDL compared to placebo (WMD = 1.37 mg/dl; 95%CI, 0.41–2.23; P = 0.005). The subgroup analysis showed that the effect of BBR supplementation on HDL was significant in studies conducted on the baseline HDL < 40 mg/dl (WMD = 1.17 mg/dl; 95%CI, 0.08 to 2.27; P = 0.035), trial duration ≤8 weeks (WMD = 2.17; 95%CI, 0.10 to 4.23; P = 0.039), intervention dose >1 g/d (WMD = 1.81; 95%CI, 0.88 to 2.73; P < 0.001), obese (>30 kg/m²) (WMD = 4.85; 95%CI, 1.52 to 8.17; P = 0.004), type 2 diabetes (WMD = 1.65; 95%CI, 0.19 to 3.10; P = 0.026), and metabolic syndrome (WMD = 6.90; 95%CI, 2.42 to 11.37; P = 0.002), and category of risk of bias of trails, high risk of bias (WMD = 1.22; 95%CI 0.08 to 2.36; P = 0.035), low risk of bias trials (WMD = 5.46; 95%CI 0.93 to 9.99; P = 0.018) (Table 3). Between study heterogeneity was observed for HDL (I² = 92.7%). The heterogeneity diminished when subgroup analysis was performed on health status including dyslipidemia (I² = 47.9%, P = 0.104), metabolic syndrome (I² = 60.8%, P = 0.078), and non-alcoholic fatty liver disease (I² = 0.00%, P = 0.988) (Table 3).

Effect of BBR supplementation on FBG

A total of 35 effect sizes from 35 studies were included in the meta-analysis of the effect of BBR supplementation on FBG (Figure 2E) (36–44, 47, 50, 54–56, 58–63, 65–67, 69, 70, 72, 74–78, 82–84). BBR supplementation significantly decreased FBG compared to placebo (WMD = −7.74 mg/dl; 95%CI, −10.79 to −4.70; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on FBG was significant in studies conducted baseline FBG ≥ 100 mg/dl (WMD = −10.61 mg/dl; 95%CI, −15.94 to −5.27; P < 0.001), trial duration >8 weeks (WMD = −10.83; 95%CI, −14.73 to −6.92; P < 0.001), intervention dose ≤1 g/d (WMD = −4.73 g/d; 95%CI, −8.75 to −0.71; P = 0.021) and >1 g/d (WMD = −9.98 g/d; 95%CI, −14.88 to −4.88; P < 0.001), normal (18.5–24.9 kg/m²) (WMD = −3.44; 95%CI, −5.75 to −1.13; P = 0.003), overweight (25–29.9 kg/m²) (WMD = −9.21; 95%CI, −12.90 to −5.52; P < 0.001), type 2 diabetes (WMD = −16.84; 95%CI, −24.51 to −9.17; P < 0.001), and non-alcoholic fatty liver diseases (WMD = −2.21; 95%CI, −4.41 to −0.02; P = 0.048), and category of risk of bias of trails, high risk of bias (WMD = −6.67; 95%CI −10.61 to −2.90; P = 0.001), moderate risk of bias (WMD = −13.56; 95%CI −26.81 to −0.31; P = 0.045) (Table 3). Between study heterogeneity was found for FBG (I² = 97.0%). The heterogeneity diminished when the subgroup analysis was performed on BMI categories including normal BMI (I² = 47.6%, P = 0.089), and obesity (I² = 14%, P = 0.322) (Table 3).

Effect of BBR supplementation on insulin

A total of 16 effect sizes from 16 studies were included in the meta-analysis of the effect of BBR supplementation on insulin (Figure 2F) (36, 38, 41, 44, 47, 56, 58, 60, 63, 67, 69, 72, 75, 76, 78, 83). BBR supplementation significantly decreased insulin compared to placebo (WMD = −3.27 mg/dl; 95%CI, −4.46 to −2.07; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on insulin was significant in studies conducted with trial duration ≤8 weeks (WMD = −3.74; 95%CI, −6.45 to −1.04; P = 0.007) and >8 weeks (WMD = −3.28; 95%CI, −5.01 to −1.54; P = 0.001), intervention dose ≤1 g/d (WMD = −2.54 g/d; 95%CI, −5.01 to −0.06; P = 0.044) and >1 g/d (WMD = −3.91; 95%CI, −5.58 to −2.24; P < 0.001), overweight (25–29.9 kg/m²) (WMD = −4.11; 95%CI, −5.87 to −2.35; P < 0.001), obese (>30 kg/m²) (WMD = −2.98; 95%CI, −4.66 to −1.29; P = 0.001), type 2 diabetes (WMD = −3.35; 95%CI, −4.98 to −1.72; P < 0.001), and others (WMD = −2.08; 95%CI, −3.74 to −0.42; P = 0.014), and category of risk of bias of trials, high risk of bias (WMD = −4.34; 95%CI −6.50 to −2.17; P < 0.001), moderate risk of bias (WMD = −1.90; 95%CI −2.42 to −1.38; P < 0.001). Between study heterogeneity was found for insulin (I² = 95.3%). The heterogeneity diminished when the subgroup analysis was performed on the risk of bias, moderate risk of bias (I² = 0.0%, P = 0.928) (Table 3).

Effect of BBR supplementation on HbA1c

A total of 21 effect sizes from 21 studies were included in the meta-analysis of the effect of BBR supplementation on HbA1c (Figure 2G) (40, 41, 43, 47–49, 54, 56–58, 65, 67, 69, 72–78). BBR supplementation significantly decreased HbA1c compared to placebo (WMD = −0.45%; 95%CI, −0.68 to −0.23; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on HbA1c was significant in studies conducted trial duration >8 weeks (WMD = −0.61; 95%CI, −0.85 to −0.232; P < 0.001), intervention dose >1 g/d (WMD = −0.64; 95%CI, −0.92 to −0.37; P < 0.001), normal (18.5–24.9 kg/m²) (WMD = 0.53; 95%CI, 0.28 to 0.79; P < 0.001), overweight (25–29.9 kg/m²) (WMD = −0.41; 95%CI, −0.53 to −0.29; P < 0.001), obese (>30 kg/m²) (WMD = −0.94; 95%CI, −1.36 to −0.53; P < 0.001), type 2 diabetes (WMD = −0.51; 95%CI, −0.87 to −0.16; P = 0.004), non-alcoholic fatty liver disease (WMD = −0.34; 95%CI, −0.46 to −0.22; P < 0.001), and category of risk of bias of trails, high risk
of bias (WMD = −0.52; 95%CI −0.77 to −0.27; P < 0.001) (Table 3). Between study heterogeneity was found for HbA1c (I² = 92.5%). The heterogeneity disappeared when subgroup analysis was performed on BMI categories including normal BMI (I² = 0.00%, P = 0.909), overweight (I² = 41.6%, P = 0.057), health status (non-alcoholic fatty liver disease) (I² = 41.7%, P = 0.180), moderate (I² = 66.9%, P = 0.082) (Table 3).

Effect of BBR supplementation on HOMA-IR

A total of 14 effect sizes from 14 studies were included in the meta-analysis of the effect of BBR supplementation on HOMA-IR (Figure 2H) (36, 38, 41, 44, 47, 48, 56, 58, 63, 67, 69, 72, 75, 78). BBR supplementation significantly decreased HOMA-IR compared to placebo (WMD = −1.04; 95%CI, −1.55 to −0.52; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on HOMA-IR was significant in studies conducted trial duration > 8 weeks (WMD = −1.13; 95%CI, −1.40 to −0.86; P < 0.001), intervention dose ≤ 1 g/d (WMD = −1.37; 95%CI, −2.12 to −0.62; P < 0.001) and > 1 g/d (WMD = −0.77; 95%CI, −1.36 to −0.18; P = 0.010), normal (18.5–24.9 kg/m²) (WMD = −0.93; 95%CI, −1.73 to −0.14; P = 0.021), overweight (25–29.9 kg/m²) (WMD = −1.03; 95%CI, −1.50 to −0.56; P < 0.001), obese (≥ 30 kg/m²) (WMD = −1.31; 95%CI, −1.90 to −0.73; P < 0.001), type 2 diabetes (WMD = −1.25; 95%CI, −1.62 to −0.88; P < 0.001) others (WMD = −0.62; 95%CI, −1.24 to −0.00; P = 0.047), and category of risk of bias of trails, high risk of bias (WMD = −1.12; 95%CI −1.59 to −0.65; P < 0.001), moderate (WMD = −1.10; 95%CI −1.18 to −1.02; P < 0.001) (Table 3). Between study heterogeneity was found for HOMA-IR (I² = 99.1%). The heterogeneity diminished when subgroup analysis was performed on BMI categories (normal) (I² = 71.9%, P = 0.059), and health status (non-alcoholic fatty liver disease) (I² = 0.0%, P = 0.518), low risk of bias (I² = 0.0%, P = 0.498) (Table 3).

Effect of BBR supplementation on SBP

A total of 20 effect sizes from 20 studies were included in the meta-analysis of the effect of BBR supplementation on SBP (Figure 2J) (37, 40, 42, 43, 47, 48, 50, 54, 55, 58, 62, 63, 65, 69, 70, 78, 79, 82, 83, 85). BBR supplementation significantly decreased SBP compared to placebo (WMD = −5.46 mmHg; 95%CI, −8.17 to −2.76; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on SBP was significant in studies conducted baseline SBP < 120 mmHg (WMD = −2.93 mmHg; 95%CI, −4.09 to −1.76; P < 0.001), and ≥ 120 mmHg (WMD = −10.29; 95%CI, −16.75 to −3.82; P = 0.002), trial duration ≤ 8 weeks (WMD = −6.83; 95%CI, −11.98 to −1.68; P = 0.009) and > 8 weeks (WMD = −4.68; 95%CI, −7.99 to −1.36; P = 0.006), intervention dose ≤ 1 g/d (WMD = −3.85; 95%CI, −7.50 to −0.19; P = 0.039) and > 1 g/d (WMD = −7.58; 95%CI, −11.79 to −3.36; P < 0.001), overweight (25–29.9 kg/m²) (WMD = −5.20; 95%CI, −8.48 to −1.92; P = 0.002), obese (≥ 30 kg/m²) (WMD = −9.69; 95%CI, −15.77 to −3.60; P = 0.002), type 2 diabetes (WMD = −6.69; 95%CI, −11.29 to −2.68; P = 0.001), metabolic syndrome (WMD = −7.09; 95%CI, −8.49 to −2.91; P < 0.001), others (WMD = −3.76; 95%CI, −6.97 to −0.53; P = 0.022), and high risk of bias (WMD = −6.73; 95%CI, −10.19 to −3.27; P < 0.001), moderate (WMD = −2.27; 95%CI −4.33 to −0.21; P = 0.030) (Table 3). Between study heterogeneity was found for SBP (I² = 86.3%). The heterogeneity diminished when subgroup analysis was conducted on baseline SBP (I² = 0.0%, P = 0.480), BMI categories (I² = 0.0%, P = 0.363), and health status including dyslipidemia (I² = 0.0%, P = 0.779), metabolic syndrome (I² = 0.0%, P = 0.839), other health status (I² = 21.1%, P = 0.281), and moderate risk of bias (I² = 0.0%, P = 0.667) (Table 3).

Effect of BBR supplementation on DBP

A total of 20 effect sizes from 20 studies were included in the meta-analysis of the effect of BBR supplementation on DBP (Figure 2J) (37, 40, 42, 43, 47, 48, 50, 54, 55, 58, 62, 63, 65, 69, 70, 78, 79, 82, 83, 85). The effect of BBR supplementation on DBP was non-significant (WMD = −2.74 mmHg; 95%CI, −5.63 to 0.15; P = 0.063). The subgroup analysis showed that the effect of BBR supplementation on DBP was significant in studies conducted on trial duration ≤ 8 (WMD = −3.12; 95%CI, −5.47 to −0.77; P = 0.009), and intervention dose > 1 (WMD = −2.95; 95%CI, −4.90 to −1.00; P = 0.003), metabolic syndrome (WMD = −5.18; 95%CI, −6.91 to −3.45; P < 0.001) (Table 3). Between study heterogeneity was found for DBP (I² = 94.9%). The heterogeneity diminished when subgroup analysis was conducted on BMI categories (I² = 0.0%, P = 0.628), health status including dyslipidemia (I² = 15.7%; P = 0.276), metabolic syndrome (I² = 0.0%, P = 0.502), and moderate (I² = 0.0%, P = 0.734) (Table 3).

Effect of BBR supplementation on CRP

A total of nine effect sizes from nine studies were included in the meta-analysis of the effect of BBR supplementation on CRP (Figure 2K) (39, 42, 43, 46, 51, 59, 78, 81, 83). The effect of BBR supplementation on CRP was non-significant (WMD = 0.05; 95%CI, −0.59 to 0.68; P = 0.887). The subgroup analysis showed that the effect of BBR supplementation on CRP was significant in studies conducted on intervention dose ≤ 1 g/d (WMD = −0.56; 95%CI, −0.87 to −0.25; P < 0.001), BMI categories (WMD = −1.06; 95%CI, −1.77 to −0.34; P = 0.003) (Table 3). Between study heterogeneity was found for CRP (I² = 97.4%) (Table 3).
Effect of BBR supplementation on IL-6

A total of four effect sizes from four studies were included in the meta-analysis of the effect of BBR supplementation on IL-6 (Figure 2L) (39, 59, 78, 83). The effect of BBR supplementation on IL-6 was non-significant (WMD = −0.53; 95%CI, −1.11 to 0.05; P = 0.073). The subgroup analysis showed that the effect of BBR supplementation on IL-6 was significant in studies conducted on trial duration ≤8 weeks (WMD = −0.56; 95%CI, −1.21 to 0.08; P < 0.001), intervention dose ≤1 g/d (WMD = −0.55; 95%CI, −0.74 to −0.36; P < 0.001), and BMI categories (WMD = −0.56; 95%CI, −0.75 to −0.37; P ≤ 0.001) (Table 3). Between study heterogeneity was found for IL-6 (I² = 94.7%). The heterogeneity diminished when subgroup analysis was conducted on intervention dose ≤1 g/d (I² = 0.0%, P = 0.766) (Table 3).

Effect of BBR supplementation on weight

A total of 21 effect sizes from 21 studies were included in the meta-analysis of the effect of BBR supplementation on weight (Figure 2M) (37, 40, 41, 45, 47, 49, 50, 54, 55, 58, 60, 61, 65, 67, 72, 78, 83, 84). BBR supplementation significantly decreased weight compared to placebo (WMD = −0.84; 95%CI, −1.34 to −0.34; P < 0.001). The subgroup analysis showed that the effect of BBR supplementation on weight was significant in studies conducted on trial duration >8 weeks (WMD = −0.87; 95%CI, −1.44 to −0.31; P = 0.002), intervention dose >1 g/d (WMD = −1.52; 95%CI, −2.40 to −0.65; P = 0.001), overweight (WMD = −0.83; 95%CI, −1.19 to −0.47; P < 0.001), type 2 diabetes (WMD = −1.58; 95%CI, −2.52 to −0.64; P = 0.001) and non-alcoholic fatty liver disease (WMD = −1.63; 95%CI, −2.97 to −0.29; P = 0.017), high risk of bias (WMD = −1.02; 95%CI, −1.53 to −0.50; P < 0.001). Between study heterogeneity was found for the weight (I² = 21.2%) (Table 3).

Effect of BBR supplementation on BMI

A total of 24 effect sizes from 24 studies were included in the meta-analysis of the effect of BBR supplementation on BMI (Figure 2N) (36, 37, 40, 41, 44, 45, 47, 48, 54, 55, 58, 60–63, 67, 69, 72, 75, 78, 79, 82–84). BBR supplementation significantly decreased BMI compared to placebo (WMD = −0.25 kg/m²; 95%CI, −0.46 to −0.04; P = 0.020). The subgroup analysis showed that the effect of BBR supplementation on BMI was significant in studies conducted on overweight (25–29.9 kg/m²) (WMD = −0.27 kg/m²; 95%CI, −0.39 to −0.15; P < 0.001) (Table 3). Between study heterogeneity was found for BMI (I² = 44.7%). The heterogeneity diminished when subgroup analysis was conducted on trial duration (I² = 0.0%, P = 0.765), intervention dose (I² = 12.6%, P = 0.316), BMI categories (I² = 0.0%, P = 0.504), and health status including dyslipidemia (I² = 0.0%, P = 0.577), metabolic syndrome (I² = 0.0%, P = 0.446), and non-alcoholic fatty liver disease (I² = 0.00%, P = 0.454), and moderate risk of bias (I² = 0.00%, P = 0.449) (Table 3).

Effect of BBR supplementation on WC

A total of 11 effect sizes from 11 studies were included in the meta-analysis of the effect of BBR supplementation on WC (36, 37, 40, 41, 48, 55, 60, 62, 72, 75, 84) (Figure 2O). BBR supplementation significantly decreased BMI compared to placebo (WMD = −1.77 kg/m²; 95%CI, −3.55 to 0.01; P = 0.005). The subgroup analysis showed that the effect of BBR supplementation on WC was significant in studies conducted on overweight (25–29.9 kg/m²) (WMD = −1.37 kg/m²; 95%CI, −2.71 to −0.03; P = 0.044), >1 g/d dose (WMD = −2.75 kg/m²; 95%CI, −3.72 to −1.77; P < 0.001) (Table 3). Between study heterogeneity was found for WC (I² = 92.9%). The heterogeneity diminished when subgroup analysis was conducted on >1 g/d dose (I² = 0.0%, P = 0.825), moderate risk of bias (I² = 0.0%, P = 0.612) (Table 3).

Effect of BBR supplementation on ALT

A total of 12 effect sizes from 12 studies were included in the meta-analysis of the effect of BBR supplementation on ALT (Figure 2P) (41, 49, 50, 52, 61, 63, 65, 73, 75, 80, 84). The effect of BBR supplementation on ALT was non-significant (WMD = −4.22; 95%CI, −8.75 to 0.31; P = 0.068) (Table 3). Between study heterogeneity was found for ALT (I² = 92.3%). The heterogeneity diminished when subgroup analysis was conducted on trial duration ≤8 weeks (I² = 0.0%, P = 0.433), intervention dose >1 g/d (I² = 48.4%, P = 0.121), overweight (25–29.9 kg/m²) (I² = 30.2%, P = 0.220), obese (>30 kg/m²) (I² = 63.2%, P = 0.066), type 2 diabetes (I² = 42.8%, P = 0.155), and other health status (I² = 69.8%, P = 0.069) (Table 3).

Effect of BBR supplementation on AST

A total of nine effect sizes from nine studies were included in the meta-analysis of the effect of BBR supplementation on AST (Figure 2Q) (41, 50, 52, 61, 63, 65, 75, 80, 84). The effect of BBR supplementation on AST was non-significant (WMD = −2.94; 95%CI, −8.68 to 2.81; P = 0.316). The subgroup analysis showed that the effect of BBR supplementation on AST was significant in studies conducted on other health statuses (WMD = 2.50; 95%CI, 0.97 to 4.03; P = 0.001) (Table 3). Between study heterogeneity was found for AST (I² = 95.8%). The heterogeneity diminished when subgroup analysis was conducted on trial duration ≤8 weeks (I² = 0.0%, P = 0.758),
intervention dose > 1 g/d ($I^2 = 0.0\%$, $P = 0.910$), BMI categories ($I^2 = 55.3\%$, $P = 0.063$), and type 2 diabetes ($I^2 = 0.0\%$, $P = 0.992$) (Table 3).

Publication bias

While the visual inspection of funnel plots showed slight asymmetries in funnel plots for all outcomes, no significant bias was detected based on Begg’s for TG, TC, LDL, HDL, FBG, insulin, HbA1c, HOMA-IR, SBP, DBP, weight, BMI, WC, ALT and Egger’s tests for CRP, IL-6, and AST (Figures 3A–Q).

Meta-regression analysis

Linear regression analyses were have done to examine if outcomes were affected by BBR doses (Figures 4A–Q) and intervention (Figures 5A–Q). A significant linear relationship between duration (weeks) and changes in BMI (coefficients $P_{\text{linearity}} = -6.64$, $P = 0.019$) (Figure 5N) and WC (coefficients $P_{\text{linearity}} = -2.83$, $P = 0.006$) (Figure 5O) was observed.

Dose-response non-linear analysis

The non-linear dose response regression analysis have applied to assess whether outcomes were affected by BBR dose (Figures 6A–Q) and intervention (Figures 7A–Q) of intervention. A significant non-linear effect of BBR dosage on serum concentrations of TG was found (coefficients $P_{\text{non-linearity}} = 34.48$, $P = 0.013$), while the association was more effective at a dose of 1 g/d (Figure 6A). A significant nonlinear effect of BBR dose was observed on serum concentration of TC (coefficients $P_{\text{non-linearity}} = 238.29$, $P = 0.007$). The effect was more prominent at a dose of 1 g/d (Figure 6A). A significant nonlinear effect of BBR dose was observed on serum concentration of TC (coefficients $P_{\text{non-linearity}} = 238.29$, $P = 0.007$). The effect was more prominent at a dose of 1 g/d (Figure 6A). A significant nonlinear association was found between BBR dose (g/d) and HDL (coefficients $P_{\text{non-linearity}} = 0.50$, $P = 0.012$), while the effect was more prominent at the dose of 5 g/d (Figure 6C). A significant non-linear effect of BBR dose (g/d) on levels of insulin was observed (coefficients $P_{\text{non-linearity}} = 1.09$, $P = 0.001$), and the effective dose of BBR was more optimum at the dose of 1.8 g/d (Figure 6F). A significant nonlinear association was found between BBR dose (g/d) and HOMA-IR (coefficients $P_{\text{non-linearity}} = 0.125$, $P = 0.001$), while the association was more effective at a dose of 1.8 g/d (Figure 6F). A significant nonlinear association was found between BBR dose (g/d) and weight (coefficients $P_{\text{non-linearity}} = -15.20$, $P = 0.043$), while the association was more prominent at the dose of 1.8 g/d (Figure 6M).

Furthermore, a significant nonlinear association was found between the duration (weeks) of BBR use and serum concentration of FBG (coefficients $P_{\text{non-linearity}} = 1,179.70$, $P = 0.001$), and the association was more effective at week 40 (Figure 7E). A significant non-linear effect of duration of BBR use (weeks) and DBP was observed (coefficients $P_{\text{non-linearity}} = 83.96$, $P = 0.001$) while the effect was more prominent at week 50 (Figure 7J). A significant nonlinear association was found between the duration (weeks) of BBR supplementation and WC (coefficients $P_{\text{non-linearity}} = 13.40$, $P = 0.005$) and the association was more effective at week 50 (Figure 7O).

Sensitivity analysis

By excluding each study, no study showed a significant impact on TG, TC, LDL, HDL, FBG, insulin, HbA1c, HOMA-IR, SBP, DBP, CRP, IL-6, AST, and weight. However, in the case of BMI, Chan et al. (40) showed a significant impact on overall effect size (WMD: $-0.23$, CI $95\%$: $-0.47$, $P = 0.0003$). Furthermore, regarding WC, León-Martínez et al. (55) (WMD: $-1.88$, CI $95\%$: $-3.72$, $-0.03$) and Mishra et al. (60) (WMD: $-2.46$, CI $95\%$: $-4.20$, $-0.72$) had a significant effect of overall effect size. Also, in terms of ALT, Zhao et al. (80) (WMD: $-5.36$, CI $95\%$: $-10.01$, $-0.71$) and Nejati et al. (61) (WMD: $-4.80$, CI $95\%$: $-9.53$, $-0.06$) showed a significant impact on overall effect size.

GRADE assessment

The GRADE profile of BBR supplementation on the outcomes with the certainty in outcomes is shown in Table 4. The risk of bias for all the outcomes was a highly serious limitation, and a very serious limitation was found for inconsistency in the outcomes. The quality of evidence was reported low for TG, TC, LDL, HDL, FBG, insulin, HbA1c, HOMA-IR, and SBP and very low for CRP, IL-6, DBP, AST, ALT, and WC except for weight and BMI that was moderate.

Discussion

This paper presents a comprehensive systematic review and dose-response meta-analysis of the effects of BBR supplementation on cardiovascular risk factors. The results showed that BBR supplementation can significantly lower TC, TG, LDL, FBG, insulin, HbA1c, HOMA-IR, SBP, weight, BMI, and WC, and can elevate HDL. According to the subgroup analysis, BBR supplementation in participants with normal BMIs (18.5–24.9) was ineffective for changing TG, TC, LDL, HDL, insulin, SBP, weight, BMI, and WC. The significant effects of BBR on HDL and WC were only seen in doses of more than 1 g/day, on FBG and HOMA-IR in the durations of more than 8 weeks, and on HbA1c and weight in both mentioned higher subgroups of dose (>1 g/d) and duration (>8 weeks). Moreover,
Funnel plots for the effect of berberine consumption on (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG (mg/dl); (F) Insulin (mg/dl); (G) HbA1c (%); (H) HOMA-IR; (I) SBP (mmHg); (J) DBP (mmHg); (K) CRP (mg/L); (L) IL-6 (mg/L); (M) weight (kg); (N) BMI (kg/m²); (O) WC (cm); (P) ALT (U/L); and (Q) AST (U/L). TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment for insulin resistance; hemoglobin A1c, HbA1c; CRP, C-reactive protein; IL-6, interleukin 6; WC, waist circumference; ALT, alanine transaminase; AST, aspartate transaminase; SBP, systolic blood pressure; DBP, diastolic blood pressure; CI, confidence interval, weighted mean difference; WMD.
FIGURE 4
Linear dose–response relations between berberine consumption and absolute mean differences. Dose–response relations between dose (g/day) and absolute mean differences in (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG (mg/dl); (F) Insulin (mg/dl); (G) HbA1c (%); (H) HOMA-IR; (I) SBP (mmHg); (J) DBP (mmHg); (K) CRP (mg/L); (L) IL-6 (ng/L); (M) weight (kg); (N) BMI (kg/m²); (O) WC (cm); (P) ALT (U/L); and (Q) AST (U/L). TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment for insulin resistance; hemoglobin A1c, HbA1c; CRP, C-reactive protein; IL-6, interleukin 6; WC, waist circumference; ALT, alanine transaminase; AST, aspartate transaminase; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Linear dose–response relations between berberine consumption and absolute mean differences. Dose–response relations between duration of intervention (week) and absolute mean differences in (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG (mg/dl); (F) Insulin

(Continued)
BBR was significantly effective in alleviating cardiovascular risk factors, mainly in subgroups with impaired metabolic health such as NAFLD, type 2 diabetes, and metabolic syndrome. In addition, BBR was effective for the improvement of LDL, HDL, and FBG only in subgroups with abnormal ranges (HDL ≤ 40, LDL > 100 mg/dl, and FBG > 100 mg/dl). In the non-linear dose-response analysis, the optimum dose for BBR was 1 g/day for TG, TC, and weight, 1.8 g/day for insulin and HOMA-IR, and 5 g/day for HDL. The most effective duration was 40 weeks for FBG and 50 weeks from beginning of BBR supplementation for DBP and WC.

Effects of BBR on FBG

BBR, a plant isoquinoline alkaloid with a long history of medical use (87), reduced FBG, insulin levels, HOMA-IR, and HbA1c in this meta-analysis significantly, and has been suggested to be significantly beneficial for the improvement of blood glucose and insulin resistance by other different meta-analyses over time (15, 16, 88, 89). Discussing the most recent studies, Ye et al., have shown in a meta-analysis of 18 clinical trials in 2021 that BBR consumption affects FBG, and HOMA-IR improvement (16). Another meta-analysis of 46 RCTs by Guo et al. (15), confirmed these results on FBG and HOMA-IR and added that 2-h postprandial blood glucose tests, fasting blood insulin, and HbA1c can be improved as well. These two studies have a good quality since they have done the risk of bias assessment, subgroup analysis, and sensitivity analysis. However, neither of them implemented dose-response analysis, which is done in this study. BBR has been known as comparable to metformin (90) and suggested as becoming an alternative to metformin in people with poor socioeconomic status (88). These effects can be owing to the activation of adenosine monophosphate-activated protein kinase (AMPK) following BBR consumption, which leads to the improvement of insulin sensitivity (16), promotion of the glucose transporters' levels (GLUT-4 and GLP-1) (16, 91), and an increase in insulin receptor expression through protein kinase C-dependent upregulation of its promoter (77, 92).

According to the subgroup analysis, it seems that BBR needs a supplementation duration of more than 8 weeks to reduce FBG, HbA1c, and HOMA-IR, and a dose of more than 1 gram per day to reduce HbA1c. This can be owing to the low bioavailability (<1%) of this substance (93). Higher doses and duration may enhance the intestinal uptake leading to more effective outcomes. Moreover, the fact that changes in HOMA-IR (94) and HbA1c (95) test results are time-consuming and occur gradually over time may justify the above results. BBR was effective in reducing FBG only in the subgroup of FBG ≥100 which can be because of the induction of higher insulin secretion in hyperglycemia by BBR, as explained by a previous study (86). Another reason can be the anti-inflammatory properties of BBR (18, 93, 96) that result in FBG reduction only when it exceeds its normal range. Hyperglycemia induces oxidative stress (97) and BBR can act against the consequential inflammation. In addition, subgroup analysis showed that the significant results can be seen only in the subgroups with unhealthy metabolic status. This evidence can also be justified by the anti-inflammatory properties of BBR (18, 93, 96). Moreover, risk of bias subgroup analysis has shown even in high risk of bias trials decreasing effect remained for all glycemic markers and even in most of them in moderate risk apart from HbA1c. Of course, the absence of this significance can probably be attributed to the small number of studies in this subgroup (n = 2).

Effects of BBR on lipid profile

This meta-analysis showed a significant effect of BBR on TG, TC, LDL, and HDL. In line with this study, all the previous meta-analyses in different years have shown beneficial effects of BBR on lipid profile improvement (12, 15, 16, 98–100). Two recent meta-analyses in 2021, done by Ye et al. (16) on 18 RCTs and by Guo et al. (15) on 46 RCTs have employed a high-quality methodology. However, this study, like other previous studies, did not do any dose-response analysis, which is presented in this study. BBR can influence the lipid profile by some main mechanisms. As mentioned before, BBR can activate AMP-activated protein kinase (AMPK). This activation leads to a reduction in fat production and changes fat accumulation to fat decomposition (16). The influence on lipid profile may also be due to intestinal absorption limitations and an increase in fecal cholesterol excretion following BBR consumption (90, 101).

In subgroup analysis, the reduction in TG and TC was significant only in participants with overweight (BMI: 25–29.9) and obesity (BMI ≥30), the significant reduction in LDL was only in the overweight subgroup, and the significant increase in HDL was only in the obese group. Moreover, the subgroups with unhealthy metabolic status and with abnormal LDL
Non-linear dose-response relations between berberine consumption and absolute mean differences. Dose-response relations between dose (g/day) and absolute mean differences in (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG (mg/dl); (F) Insulin (mg/dl); (G) HbA1c (%); (H) HOMA-IR; (I) SBP (mmHg); (J) DBP (mmHg); (K) CRP (mg/L); (L) IL-6 (ng/L); (M) weight (kg); (N) BMI (kg/m²); (O) WC (cm); (P) ALT (U/L); and (Q) AST (U/L). TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment for insulin resistance; HbA1c, hemoglobin A1c; CRP, C-reactive protein; WC, waist circumference; ALT, alanine transaminase; AST, aspartate transaminase; SBP, systolic blood pressure; DBP, diastolic blood pressure.
FIGURE 7
Non-linear dose-response relations between berberine consumption and absolute mean differences. Dose-response relations between duration of intervention (week) and absolute mean differences in (A) TG (mg/dl); (B) TC (mg/dl); (C) LDL (mg/dl); (D) HDL (mg/dl); (E) FBG.
(≥100 mg/dl) and HDL (<40 mg/dl) responded significantly to this supplementation. All these conditions are linked to the secretion of inflammatory mediators and may benefit from anti-inflammatory substances (102–104). As an anti-inflammatory agent, BBR is thought to inhibit the PI3K/AKT signaling pathway (93), suppress nuclear factor kappa B (NF-κB) signaling pathway (93, 96), and lower CRP, IL-6, and tumor necrosis factor-alpha (TNF-α) levels (18). Risk of bias subgroup analysis has shown that even in high and moderate risk of bias trials, the decreasing effect remained for all lipid profiles apart from HDL in moderate risk of bias. Of course, the absence of this significance can probably be attributed to the small number of studies in this subgroup (n = 5).

**Effects of BBR on anthropometric measures**

The present study demonstrated a significant effect of BBR on weight, BMI, and WC. Two meta-analyses by Asbaghi et al. and Xiong et al., similar to this study, revealed the significant influence of BBR supplementation on the reduction of BMI and WC (13, 14). The anti-obesity effects of BBR can be owing to some reasons. First, BBR induces thermogenic effects through the AMPK-PRDM16 axis and brown adipocyte differentiation, leading to more energy expenditure (105). Second, it can modulate the gene expression of some factors involved in adipogenesis like peroxisome proliferator-activated receptor γ (PPARγ), cAMP-response element-binding protein (CREB), GATA-2, and GATA-3 (13, 91). It is also suggested that BBR can decrease the size and number of droplets of lipids in some specific regions of the body (90). Nevertheless, unlike the study by Asbaghi et al. and Xiong et al. could not see a significant change in weight after BBR intake. The third meta-analysis of 12 trials by Amini et al. in the same year could not see any significant reduction in BMI, WC, and weight following BBR supplementation (91). However, they reported a significant reduction in the waist-to-hip ratio (WHR) (91). These controversies highlight the need for a new conclusive meta-analysis.

According to the subgroup analysis, the only BMI category in which the reduction in weight, WC, and BMI was significant was the overweight (BMI: 25–29.9). The number of trials included in this category was more than 3-folds that of the obese (BMI 30) and normal weight (BMI: 18.5–24.9) categories combined. We may see significant results in other BMI subgroups if the sample size was more. Doses of more than 1 g/day were effective for WC and BMI reduction and a duration of more than 8 weeks was effective for weight loss, which can be attributed the aforementioned low bioavailability of BBR (93). In a risk of bias subgroup analysis, it was shown in high risk of bias trials, the decreasing effect remained for weight but not for BMI. However, it seems that although BBR may affect weight, it does not have a statistically significant and considerable effect (WMD = −0.28) on BMI. However, there is a possibility of a lack of sample size and power in this subgroup.

**Effects of BBR on blood pressure**

The present study reports a significant reduction in SBP but a non-significant change in DBP following BBR supplementation. Regarding the previous studies on the effect of BBR on BP, a systematic review done in 2021 by Suadoni et al. reported that the evidence was not enough, of good quality, and suitable duration to report any significant effects (19), and a meta-analysis in 2015 by Lan et al. reported a non-significant result for this relationship on patients with type 2 diabetes (88). Another meta-analysis of 12 RCTs in 2021 showed that a supplement called Armolipid Plus, whose ingredients are BBR plus 5 other substances, was not effective in imposing changes in SBP and DBP (106). To reach a conclusive result, this meta-analysis comprehensively evaluates BBR’s effects on different cardiovascular risk factors in different subgroups, with dose-response analyses and with more included clinical trials.

Regarding the subgroup analysis, SBP was significantly reduced in all subgroups despite normal BMI, dyslipidemia, and NAFLD, in which the included trials were only 1 or 2 studies. DBP did not change in the majority of subgroups, despite being significantly lower in the intervention dose of >1. This finding highlights the need for more well-designed RCTs in the future with higher intervention doses. In risk of bias subgroup analysis has shown that in high and moderate risk of bias trials, the decreasing effect is constant for SBP. 
TABLE 4 GRADE profile of berberine supplementation on cardiovascular risk factors in adults.

| Outcomes | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | WMD (95%CI) | Quality of evidence |
|----------|--------------|---------------|--------------|-------------|-----------------|-------------|-------------------|
| TG       | High serious | Very serious  | No serious   | No serious  | No serious     | −23.70 (−30.16, −17.25) | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| TC       | High serious | Very serious  | No serious   | No serious  | No serious     | −20.64 (−23.65, −17.63) | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| LDL      | High serious | Very serious  | No serious   | No serious  | No serious     | −9.63 (−13.87, −5.39)  | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| HDL      | High serious | Very serious  | No serious   | No serious  | No serious     | 1.37 (0.41, 2.33)      | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| FBG      | High serious | Very serious  | No serious   | No serious  | No serious     | −7.74 (−10.79, −4.70)  | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| Insulin  | High serious | Very serious  | No serious   | No serious  | No serious     | −3.27 (−4.46, −2.07)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| HbA1c    | High serious | Very serious  | No serious   | No serious  | No serious     | −0.45 (−0.68, −0.23)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| HOMA-IR  | High serious | Very serious  | No serious   | No serious  | No serious     | −1.04 (−1.55, −0.52)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| SBP      | High serious | Very serious  | No serious   | No serious  | No serious     | −5.46 (−8.17, −2.76)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| DBP      | High serious | Very serious  | No serious   | No serious  | No serious     | −2.74 (−5.63, 0.15)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| CRP      | High serious | Very serious  | No serious   | Serious limitation b | No serious | −0.05 (−0.59, 0.68)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| IL-6     | High serious | Very serious  | No serious   | No serious  | No serious     | −0.53 (−1.11, 0.05)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| Weight   | High serious | No serious    | No serious   | No serious  | No serious     | −0.84 (−1.34, −0.34)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| BMI      | High serious | No serious    | No serious   | No serious  | No serious     | −0.25 (−0.46, −0.04)   | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| WC       | High serious | Very serious  | No serious   | Serious limitation b | No serious | −1.77 (−3.55, 0.01)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| ALT      | High serious | Very serious  | No serious   | No serious  | No serious     | −4.22 (−8.75, 0.31)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| AST      | High serious | Very serious  | No serious   | Serious limitation b | No serious | −2.94 (−8.68, 2.81)    | ⊗ ⊗ ○○ ○○ ○○ ○○ |
| "There is significant heterogeneity for TG (I² = 96.6%), TC (I² = 85.4%), LDL (I² = 96.1%), HDL (I² = 92.7%), FBG (I² = 97.0%), Insulin (I² = 95.3%), HbA1C (I² = 92.5%), HOMA-IR (I² = 99.1%), SBP (I² = 86.3%), DBP (I² = 94.9%), CRP (I² = 97.4%), IL-6 (I² = 94.7%), WC (I² = 92.9%), ALT (I² = 92.3%), and AST (I² = 95.8%).
| "There is no evidence of significant effects of berberine consumption on DBP, CRP, IL-6, WC, ALT, and AST.
| ⊗ shows +1 quality evidence that for every serious limitation, one of these quality evidences is lost.

Effects of BBR on inflammatory markers

This meta-analysis could not see any significant changes in two main inflammatory markers, CRP and IL-6, following the supplementation with BBR that was not expected regarding the anti-inflammatory properties of BBR. This result is in contrast with the meta-analysis of 12 RCTs by Asbaghi et al. (13) that found a significant effect of this agent on CRP levels. Another previous meta-analysis of five non-heterogeneous RCTs by Beba et al. (17) supported the hypothesis of CRP reduction after BBR supplementation. Guo et al. have done another meta-analysis of 46 studies in 2021 and have found an effective reduction in IL-6, TNF-α, and CRP following BBR intake (15). A meta-analysis of 52 RCTs by Lu et al. (18) reported a significant BBR-induced reduction in these two inflammatory markers (CRP and IL-6). However, the participants of this study were only Chinese people, and the result should not be generalized (18). Generally, different factors can justify the contradictory results.
between the studies such as different races, genetics, sex, or age range of participants, different study durations, sampling methods; supplement form or dose, and other reasons that cause heterogeneity. Moreover, in the present analysis, only 4 studies were included for IL-6 and 9 studies were included for CRP hence the sample size was small.

Effects of BBR on liver enzymes

Similar to two previous meta-analyses, one from 12 RCTs by Asbaghi et al. (13), and another from 5 trials by Mohtashamnia et al. (107), our results did not show any significant effect of BBR on liver function enzymes (ALT and AST). The effect of BBR on liver function enzymes was not seen in either of the subgroups.

In the non-linear dose-response analyses, we found that the approximate optimum dose for BBR supplementation for the reduction of TG, TC, and weight is 1 g/day. This dose is 1.8 g/day for insulin and HOMA-IR, and 5 g/day for HDL improvement. The most effective duration for BBR intake was 40 weeks for FBG and 50 weeks for DBP and WC from beginning of supplementation. Although the plasma concentration of BBR tends to be low owing to its poor oral absorption and bioavailability, its concentration in different tissues usually remains high (108). The pharmacokinetic profile of BBR indicated that its concentration in most tissues was higher than in plasma 4 h after administration (109). This characteristic of BBR may cause saturation of the body with it at high doses and durations and can be the reason why the supplementation of more than a specific dose or duration seems to be pointless in this analysis.

BBR has attracted many scientists’ attention owing to its ameliorative effects on CVD risk factors (6, 7, 16, 77). The mechanisms by which BBR affects metabolic health are diverse and well-defined. BBR is suggested to upregulate the expression of LDL receptors in the human hepatoma cell line (HepG2) and to inhibit both cholesterol and TG synthesis in the liver, dose-dependently (110). This effect of BBR on lipid synthesis is mediated by the mitogen-activated protein kinase (MAPK/ERK) pathway (110), and can also be owing to the decrease in proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. PCSK9 downregulates the LDL receptor (LDLR) and BBR acts against it (111). Another mechanism of action for BBR could be that it is an agonist for AMPK, a fuel gauge. This activation leads to the inhibition of cholesterol and TG synthesis by inactivating two enzymes, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) and ACC (acetetyl-coenzyme A carboxylase) (110). AMPK activation also increases energy production hence normalizing the imbalance between glucose, lipid, and energy (16). This activation can also impose anti-inflammatory effects (112) and can speed up the transport of glucose in the serum by promoting glucose transporter type 4 (GLUT4) translocation (113). It is proposed by Zhang et al. that BBR can also increase the expression of the insulin receptor in a variety of human cells in type 2 diabetic patients (77). Li et al. induced hyperlipidemia in hamsters by feeding them with a high-fat diet and assessed the effect of BBR supplementation on this hyperlipidemia. The excretion of cholesterol to the liver, bile, and feces was promoted following BBR intake in hyperlipidemic hamsters but not in the normal group (114). Therefore, BBR seems to be a multi-targeted lipid-lowering agent. BBR, as an anti-inflammatory agent, is suggested to inhibit the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway which reduces the secretion of pro-inflammatory cytokines or mediators in cardiomyocytes and serum, such as IL-6, Interleukin 1 beta (IL1β), CRP, and TNF-α (18, 93), and it can also suppress nuclear factor kappa B (NF-kB) signaling pathway (93, 96). Moreover, BBR induces thermogenic effects through the AMPK-PDML16 axis that induces brown adipogenesis, leading to more energy expenditure (105). BBR can also suppress the expression of some factors involved in adipogenesis like PPARγ (115), CREB (116), GATA-2, and GATA-3 (117). It is also suggested that BBR can decrease the size and number of droplets of lipids in the 3T3-L1 adipocyte cell line (90). The other anti-diabetic mechanism of BRB is related to the modulating of gut microbiota (118). This agent works topically in the gastrointestinal tract as an antimicrobial agent to act against pathogens and inhibit their growth and block their adhesion to epithelial cells (118). The other protective role of BBR for the cardiovascular system can be the anti-hypertensive effects owing to its impact on vasodilation in middle cerebral arteries in rats (119), and its action against the renin-angiotensin system in rats (120). BBR attenuated ischemic-induced arrhythmias in diabetic rats via recovering depressed I (to) and I (Ca) currents (121).

This meta-analysis has various strengths and limitations. one of the most important strengths of this study can be considered the most comprehensive meta-analysis to date regarding the relationship between BBR and all different cardiovascular risk factors with a dose-response analysis with the larger sample size compared to the previous similar meta-analysis (13, 14, 16, 91, 99). Studies were included based on inclusion criteria, with varying individuals, which provides the possibility of subgroup analysis. The randomized and placebo-controlled design of all included trials and the double-blind design of most of them can also be other strengths. Another point to be mentioned is that the participants of the included trials were from different nations, of different ages and sexes, and with different existing morbidities such as NAFLD, metabolic syndrome, etc. This may enhance heterogeneity but can also make the results admissible to be generalized. No limitations on language and time for including studies. In addition, sensitivity tests in this study were used to identify potential sources of heterogeneity among trials. GRADE tools for quality assessment of studies and subgroup analysis especially for risk of bias have done. However, some limitations should be considered. Although all studies used randomization, information on allocation
concealment, randomization efficiency, and withdrawal was not consistently disclosed. In the approach of statistical analysis, the control of covariate and confounding variables was not done in all studies. Small study sample sizes made randomization’s capacity to lessen the potential effects of confounding variables difficult. The included studies were significantly heterogeneous. Regarding the considerable number of the included studies, the types of measurements for outcomes could be different. Intra assay coefficient of variation and inter-assay variability for biochemical kits in different studies might lead to different results. Same thing about, the anthropometric indices were measured by different scales and differently trained persons in the included studies. In addition, the blood pressure had been taken in different positions (seated or standing posture, supine position). Different sources of BBR supplementation in studies were used in the trials. In addition, in the analyses for liver enzymes and inflammatory markers, the number of included trials was small, hindering reliable results. Lastly according to risk of bias assessment, most of the included RCTs in this study has a high risk of bias. This highlights the need for more well-designed clinical trials in the future.

Conclusion

This systematic review and dose-response meta-analysis found a significant improvement in lipid profiles, insulin resistance, and anthropometric measures associated with BBR supplementation. However, no significant changes have been observed in liver enzymes or inflammatory markers. Therefore, BBR may be an effective supplement for the improvement of metabolic syndrome and cardiovascular risk. To comprehend how BBR affects these outcomes in people, mechanistic research, homogeneous RCTs, and future investigations are required.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

MZam designed the study. MZam and OA developed the search strategy and assessed the risk of bias in the meta-analyses. MZam, MN-S, and OA extracted the data and conducted the analyses. SH and MZar drafted the manuscript. FS, OA, and MN-S interpreted the results. FS and OA revised the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Ruiz-Moreno C, Lara B, Salmero JJ, Brito de Souza D, Ordovás JM, Del Coso J. Time course of tolerance to adverse effects associated with the ingestion of a moderate dose of caffeine. Eur J Nutr. (2020) 59:3293–302. doi: 10.1007/s00394-019-02167-2
2. Sharifi-Rad J, Rodrigues CF, Sharopov F, Focca AO, Can Karaca A, Sharifi-Rad M, et al. Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds. Int J Environ Res Public Health. (2020) 17:2326. doi: 10.3390/ijerph17072326
3. Szczepańska E, Białek-Dratwa A, Janota B, Kowalski O. Dietary therapy in prevention of cardiovascular disease (CVD)-tradition or modernity? A review of the latest approaches to nutrition in CVD. Nutrients. (2022) 14:2649. doi: 10.3390/nu14122649
4. Pierpoli MF, Hoes AW, Agewal S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. (2016) 37:2315–81. doi: 10.1093/eurheartj/ehw106
5. Kumar A, Ekavali, Chopra K, Mukherjee M, Pottubathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. (2015) 761:288–97. doi: 10.1016/j.ejphar.2015.05.068
6. Rui R, Yang H, Liu Y, Zhou Y, Xu X, Li C, et al. Effects of berberine on atherosclerosis. Front Pharmacol. (2021) 12:764175. doi: 10.3389/fphar.2021.764175
7. Cao RY, Zheng Y, Zhang Y, Jiang L, Li Q, Sun W, et al. Berberine on the prevention and management of cardiometabolic disease: clinical applications and mechanisms of action. Am J Chin Med. (2021) 49:1645–66. doi: 10.1142/S0192415X21500762
8. Walden R, Tomlinson B. Cardiovascular Disease. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. Boca Raton, FL: CRC Press/Taylor & Francis (2011).
9. Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W, et al. A new therapeutic candidate for cardiovascular diseases: berberine. Front Pharmacol. (2021) 12:631100. doi: 10.3389/fphar.2021.631100
10. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. (2012) 12:1113–24. doi: 10.1517/14712598.2012.704014
Hajizadeh-Sharafabad F, et al. The effect of vitamin D-calcium co-supplementation on inflammatory biomarkers: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr ESPEN*. (2020) 38.43–9. doi: 10.1016/j.clnesp.2020.04.010

Xiong P, Niu L, Taialei S, Kord-Vazkhanen H, Clark CCT, Gáman MA, et al. The effect of berberine supplementation on obesity indices: a dose-response meta-analysis and systematic review of randomized controlled trials. *Complement Ther Clin Pract*. (2020) 39:101113. doi: 10.1016/j.ctcp.2020.101113

Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, et al. The Effect of Berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. *Oxid Med Cell Longev*. (2021) 2021:2074610. doi: 10.1155/2021/2074610

Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, et al. Efficacy and safety of berberine alone for several metabolic disorders: a systematic review and meta-analysis of randomized clinical trials. *Front Pharmacol*. (2021) 12:653887. doi: 10.3389/fphar.2021.653887

Beba M, Djafarian K, Shah-Bidar S. Effect of Berberine on C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. *Complement Ther Med*. (2018) 336:924–6. doi: 10.1136/bmj.39489.470347.AD

Suadoni MT, Atherton I. Berberine for the treatment of hypertension: a systematic review. *Complement Ther Clin Pract*. (2021) 42:102187. doi: 10.1016/j.ctcp.2021.102187

Moher D, Liberati A, Tetzlaff J, Altman D, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, et al. Glean-3: an atlas for an alphabet of diseases, from A to Z. *Int J Mol Sci*. (2018) 19:379. doi: 10.3390/ijms19020379

Guyatt G, Oxman A, Vist G, Kunz R, Fisser P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. (2008) 336:924–6. doi: 10.1136/bmj.39489.470347.AD

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2

Asbaghi O, Sadeghian M, Mozaffari-Khosravi H, Maleki V, Shokri A, Hajizadeh-Sharafabad F, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr ESPEN*. (2020) 38.43–9. doi: 10.1016/j.clnesp.2020.04.010

An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. *Clin Endocrinol*. (2014) 80:425–31. doi: 10.1111/cen.12294

Aryaeian N, Sedehi SK, Khorszad M, Zarezadeh M, Hosseinia A, Shahram F. Effects of hydroalcoholic extract of Berberis integrifolia on the anthropometric indices and metabolic profile in active rheumatoid arthritis patients. *Complement Ther Med*. (2020) 50:102331. doi: 10.1016/j.ctim.2020.102331

Asemiani S, Montazeri V, Baradaran B, Tabatabaei MF, Pirouroopan S. The effects of Berberis vulgaris juice on insulin indices in women with benign breast disease: a randomized controlled clinical trial. *Iran J Pharm Res IJPR*. (2018) 17(Suppl):110–21

Cao C, Su M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. *Exp Ther Med*. (2019) 17:3009–14. doi: 10.3892/etm.2019.7295

Chan M, Qin Z, Man SC, Lam M, Lai WH, Ng RM, et al. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. *Psychiatria Clin Neurosci*. (2022) 76:77–85. doi: 10.1111/pcn.13132

Chang X, Wang Z, Zhang Z, Yan H, Bian H, Xia M, et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. *J Transl Med*. (2016) 14:246. doi: 10.1186/s12967-016-0982-x

Cheng F, Wang Y, Li J, Su C, Wu F, Xia W-H, et al. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. *Int J Cardiol*. (2013) 167:936–42. doi: 10.1016/j.ijcard.2012.03.090

Dai P, Wang I, Lin L, Zhang Y, Wang Z. Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. *Exp Ther Med*. (2015) 10:869–76. doi: 10.3892/etm.2015.2585

Emamati H, Asadian S, Zahehri A, Ghanavati M, Nasrollahzadeh J. The effect of berberine (Berberis vulgaris) consumption on flow-mediated dilation and metabolic syndrome components. *Iran J Endocrinol Metabol*. (2017) 19:e96411. doi: 10.15171/ijem.2017.001

Fei-Qi-Z, Lue C, Jin-hua Z. Influence of berberine combination with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke. *J Contemp Neurol Neurosurg*. (2015) 15:43. doi: 10.3968/j.issn.1672-6731.2015.01.010

Fu R, Gartlehner G, Grant M, Shadish WR, Armstrong JC, Lin L, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. *Nat Commun*. (2012) 35:2607–15. doi: 10.1038/ncomms7000

Guo Y, Zhang Y, Shi X, Li X, Hong J, Chen J, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabolomics. *Talanta*. (2010) 81:766–72. doi: 10.1016/j.talanta.2010.01.015

Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, et al. Biopsychosocial analysis, metabolic effects and safety of the association Berberis aristata/Biloba marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. *J Biol Regul Homeost Agents*. (2017) 31:495–502.

Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, et al. A Phase 2, proof of concept, randomized controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. *Nat Commun*. (2012) 3:5033. doi: 10.1038/ncomms6172

Kashkooli RI, Najafi SS, Sharifi H, Hamedi A, Asl MKH, Kalyani MN, et al. The effect of Berberis vulgaris extract on transaminase activities in non-alcoholic fatty liver disease. *Hepatitisc. Monthly*. (2015) 15:e25067. doi: 10.5812/hepatimon.25067

Khorszad M, Sedehi SK, Aryaeian N, Shahram F, Akbari-Ali Ghiasi M, Mahmodi M, Motavali M, et al. Effects of hydroalcoholic extract of Berberis integrifolia in the clinical signs, hs-CRP, TNFα, and ESR in active rheumatoid arthritis patients. *J Herbal Med*. (2021) 28:100444. doi: 10.1016/j.jhermed.2021.100444
Berberine and insulin resistance in berberine-treated type 2 diabetic patients: a randomized controlled clinical trial. J Med Food (2021) 24:111-5. doi: 10.1089/jmf.2020.0029

Li M, Li Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, et al. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. (2021) 300:113899. doi: 10.1016/j.psychres.2021.113899

Mansournia A, Sadeghizadeh M, Mir H, Keshavarz N, editors. Investigating the effect of barberry juice consumption on glycated hemoglobin in patients with type II diabetes. Indo Am J Pharm Sci. (2017) 4:4610-4. doi: 10.5281/zenodo.1102321

Memon MA, Khan RN, Riaz S, Ain QU, Ahmed M, Kumar N. Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients. J Res Med Sci. (2018) 23:110. doi: 10.4103/jrms.JRMS_1078_17

Meng S, Wang LS, Huang QZ, Zhou Q, Sun YG, Cao JT, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. (2012) 39:406-11. doi: 10.1111/j.1440-1681.2012.05670.x

Mishra N, Verma R, Jadaun P. Study on the effect of berberine, myoinositol, and metformin in women with polycystic ovary syndrome: a prospective randomised study. Cureus. (2022) 14:21781. doi: 10.7759/cureus.21781

Nejati L, Alizadeh A, Salari GR, Moomeinoddin R, Nejati P. The effect of berberine on lipid profile, liver enzymes, and fasting blood glucose in patients with non-alcoholic fatty liver disease (NAFLD): a randomized controlled trial. Med J Islam Repub Iran (MJIR). (2022) 36:287-94. doi: 10.17683/mjir.36.39

Pérez-Rubio KG, González-Ortiz E, Martínez-Abundis E, Robles-Cervantes IA, Espiné-Bermúdez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. (2013) 11:366-9. doi: 10.1089/met.2012.0183

Rashidi H, Namjouy F, Mehrbani Z, Zakerkash M, Ghaderian SB, Latifi SM. The effects of active ingredients of barberry root (Berberis) on glycemic control and insulin resistance in type 2 diabetic patients. Jundishapur J Nat Pharm Sci. (2018) 13:e46180. doi: 10.5812/jnps.64180

Salehzadeh H, Iloue Kashkooli R, Najafi SS, Hossein Ask SLK, Hamedi A, Kalateh Sadat A. The effect of Berberis vulgaris extract on blood pressure and weight of the patients suffered from non-alcoholic fatty liver disease. J Res Dev Nurs Midwifery. (2013) 10:121-7.

Sanjari M, Shamsinejad B, Khazaeli P, Safi Z, Mirrashidi F, Neghabzadeh-Tahami A. Safety and efficacy of Berberis integrerrima root extract in patients with type 2 diabetes. A parallel intervention based triple blind clinical trial. J Diab Metab Disord. (2020) 19:71-80. doi: 10.5403/jdmd.2020.019-00478.x

Sharma RK, Sharma B, Jindal M, Gupta AK, Kunwar R, Lata S, et al. Evaluation of hypolipidemic effect of stem part of Berberis aristata in Type 2 diabetes mellitus patients as add on therapy. Nut J Physiol Pharmacol. (2017) 7:1159. doi: 10.5455/njppp.2017.7.015710006217

Shidfar F, Ebrahimsi SS, Hossein S, Heydari I, Shidfar H, Hajhashemi G. The effects of Berberis vulgaris fruit extract on serum lipoproteins, apol, apol-A-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients. Iran J Physiol Pharm R. (2012) 11:643. doi: 10.22037/ippr.2012.11.055

Sohrab G, Eskhavari N, Hedayati M. Effect of berberine juice consumption on blood pressure in patients with type 2 diabetes. Res Med. (2016) 39:183-8. Available online at: http://pejouhesh.sbmu.ac.ir/article-1-1488-en.html

Soltani R, Ghanadian SM, Iraj B, Homayouni A, Esfahani TS, Alkami B. The Effects of Berberis integrerrima fruit extract on glycemic control parameters in patients with type 2 diabetes: a randomized controlled clinical trial. Evid Based Complement Alternat Med. (2021) 2021:5583691. doi: 10.1155/2021/5583691

Tahmasebi L, Zakerkash M, Gofarahrakhab F, Namjouy F. Randomised clinical trial of Berberis vulgaris root extract on glycemic and lipid parameters in type 2 diabetes mellitus patients. Eur J Integr Med. (2019) 32:100998. doi: 10.1016/j.eurijim.2019.100998

Wang S, Ren H, Zhong H, Zhao X, Li C, Ma J, et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double-blind placebo controlled randomized study. Gut Microbes. (2022) 14:2003176. doi: 10.1080/19490976.2021.2003176

Wu X, Li Q, Xin H, Yu Z, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. J Clin Pharmacol. (2005) 61:567-72. doi: 10.1002/jcph.200509-05952-3

Yan H, Xia M, Chang X, Bian H, Xu Q, Gao X, et al. editors. Pioglitazone versus berberine for treatment of non-alcoholic fatty liver disease patients with impaired glycated regulation or type 2 diabetes mellitus. Diabetesologia (2012) 55:536-536. doi: 10.1007/s00125-012-2688-9

Yan H-M, Xia M-E, Wang Y, Chang X-Z, Yao X-S, Yao J-L, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS ONE. (2015) e0134172. doi: 10.1371/journal.pone.0134172

Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. (2008) 57:512-7. doi: 10.1016/j.metabol.2007.07.029

Zhang H, Wei J, Xue R, Wu J-D, Zhao W, Wang Z-Z, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. (2010) 59:285-92. doi: 10.1016/j.metabol.2009.07.029

Zhang Y, Li L, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. (2008) 93:2559-65. doi: 10.1210/jc.2007-2040

Zhao J, Yeung W-F, Chan Y-H, Vackova D, Leung JY, Ip DK, et al. Effect of berberine on cardiovascular disease risk factors: a mechanistic randomized controlled trial. Nutrients. (2011) 13:2550. doi: 10.3390/nu13082550

Zhao W, Xue R, Zhou Z-X, Kong W-J, Jiang J-D. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother. (2008) 62:730-1. doi: 10.1016/j.biopha.2008.01.007

Zilaei A, Mokhberie K, Tavalee S, Salehi M, Ghayour-Mobarhan M, Fern GA. Barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity c-reactive protein in patients with metabolic syndrome: a double-blind, randomized placebo-controlled trial. Phytother Res. (2014) 28:1211-5. doi: 10.1002/ptr.5117

Zilaei A, Mokhberie K, Mokhberie M, Teimany M, Emanian M, Mobarhan M, Ferns G. Effect of berberine treatment on blood pressure in patients with metabolic syndrome. J Nutr Pharmacol. (2015) 8:59-63.
review and meta-analysis of randomized controlled trials. *Complement Ther Med.* (2020) 49:102337. doi: 10.1016/j.ctim.2020.102337

92. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, et al. Berberine alleviates insulin-related glucose-lowering effects and C-peptide-independent regulation of insulin receptor expression. *Metabolism.* (2009) 58:109–19. doi: 10.1016/j.metabol.2008.08.013

93. An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, et al. Promising antioxidative effect of berberine in cardiovascular diseases. *Front Pharmacol.* (2022) 13:865533. doi: 10.3389/fphar.2022.865533

94. Morimoto A, Tatsumi Y, Sozano F, Miyamaatsu N, Sonoda N, Godai K, et al. Increase in homestasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion: the Sakai study. *PloS ONE.* (2014) 9:e105827. doi: 10.1371/journal.pone.0105827

95. Lind M, Provodic A, Ceo-Soriano L, Norman O, Persson NG, Garcia-Rodriguez LA. Changes in Hba1c and frequency of Hba1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. *Diabetologia.* (2014) 57:1586–94. doi: 10.1007/s00125-014-3250-8

96. Li CL, Tan LH, Wang YF, Luo CD, Chen HB, Lu Q, et al. Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma coptidis on macrophage activation. *Cell Death Dis.* (2020) 11:30789. doi: 10.1038/s41419-019-1706-y

97. Akhri M, Hassan-Zadeh V. Hyperglycemia affects the expression of inflammatory genes in peripheral blood mononuclear cells of patients with type 2 diabetes. *Immunol. Invest.* (2018) 47:654–65. doi: 10.1080/08888631.2018.1480031

98. Zhao Y, Yang YT, Du YW, Yang HM, Wu SX. Systematic review and Meta-analysis on efficacy and safety of berberine for diabetes and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. *Diabetologia.* (2014) 57:1586–94. doi: 10.1007/s00125-014-3250-8

99. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systematic review and meta-analysis of randomized controlled trials. *Planta Med.* (2013) 79:437–43. doi: 10.1055/s-0032-1328321

100. Banach M, Patti AM, Giggio JV, Cicero AFG, Athanasov AG, Bajraktari G, et al. The role of natriuretic peptides in statin intolerant patients. *J Am Coll Cardiol.* (2018) 72:96–118. doi: 10.1016/j.jacc.2018.04.040

101. Asrith M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. *J Endocrinol.* (2013) 218:R25–36. doi: 10.1530/JOE-13-0201

102. Feng X, Sureda A, Safari S, Memariani Z, Tewari D, Annuazista G, et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. *Theranostics.* (2019) 9:1923–51. doi: 10.7150/thno.30787

103. Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. *Med Sci Monit.* (2017) 23:191–204. doi: 10.12659/msm.881842

104. Feng X, Sureda A, Safari S, Memariani Z, Tewari D, Annuazista G, et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. *Theranostics.* (2021) 13:638. doi: 10.3390/nu13020638

105. Mohtashaminia F, Amini MR, Sheikholessein F, Djafarian K, Shah Bidar S. Effects of berberine-silymarin on liver enzymes: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr ESPEN.* (2022) 49:181–6. doi: 10.1016/j.clnesp.2022.10.037

106. Feng X, Sureda A, Safari S, Memariani Z, Tewari D, Annuazista G, et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. *Theranostics.* (2019) 9:1923–51. doi: 10.7150/thno.30787

107. Lou T, Zhang Z, Xi Z, Liu K, Li L, Liu B, et al. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. *Inflammation.* (2011) 34:659–67. doi: 10.1007/s10753-010-9276-2

108. Morimoto A, Tatsumi Y, Soyano F, Miyamaatsu N, Sonoda N, Godai K, et al. Increase in homestasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion: the Sakai study. *PloS ONE.* (2014) 9:e105827. doi: 10.1371/journal.pone.0105827

109. Lind M, Provodic A, Ceo-Soriano L, Norman O, Persson NG, Garcia-Rodriguez LA. Changes in Hba1c and frequency of Hba1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. *Diabetologia.* (2014) 57:1586–94. doi: 10.1007/s00125-014-3250-8

110. Li CL, Tan LH, Wang YF, Luo CD, Chen HB, Lu Q, et al. Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma coptidis on macrophage activation. *Cell Death Dis.* (2020) 11:30789. doi: 10.1038/s41419-019-1706-y

111. Akbani M, Hassan-Zadeh V. Hyperglycemia affects the expression of inflammatory genes in peripheral blood mononuclear cells of patients with type 2 diabetes. *Immunol. Invest.* (2018) 47:654–65. doi: 10.1080/08888631.2018.1480031

112. Lou T, Zhang Z, Xi Z, Liu K, Li L, Liu B, et al. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. *Inflammation.* (2011) 34:659–67. doi: 10.1007/s10753-010-9276-2